

# CITATION REPORT

List of articles citing

## Tribute to Patrick Steptoe: beginnings of laparoscopy

DOI: 10.1093/humrep/4.suppl\_1.1  
Human Reproduction, 1989, 4, 1-9.

**Source:** <https://exaly.com/paper-pdf/20958265/citation-report.pdf>

**Version:** 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
970	Serum markers for gynaecological cancer in the reproductive years. 155-178		
969	Serum half-life of the tumor marker CA 125 during induction chemotherapy as a prognostic indicator for survival in ovarian carcinoma. <b>1990</b> , 69, 423-9		28
968	Serum levels of CA 125 during the first trimester of normal outcome, ectopic and anembryonic pregnancies. <i>Human Reproduction</i> , <b>1990</b> , 5, 116-22	5.7	18
967	A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. <b>1990</b> , 97, 922-9		605
966	The effect of abdominal surgery on the serum concentration of the tumour-associated antigen CA 125. <b>1990</b> , 97, 934-8		30
965	Occurrence of the mucinous differentiation antigen CA125 in genital tract and conductive airway epithelia of diverse mammalian species (rabbit, dog, monkey). <b>1990</b> , 45, 192-8		19
964	Production of various marker substances in human ovarian cancer cell lines of epithelial origin. <b>1990</b> , 248, 103-10		5
963	Gynecologic tumor markers. <b>1990</b> , 6, 305-13		14
962	Serum concentrations of CA 125 and aminoterminal propeptide of type III procollagen (PIIINP) in patients with endometrial carcinoma. <i>Cancer</i> , <b>1990</b> , 66, 2399-406	6.4	16
961	Development of assisted conception. <b>1990</b> , 46, 565-79		15
960	Reactivity of Polyclonal and Two Monoclonal Antibodies with Cell Subsets Isolated from Cystic Fluids of Ovarian Serous Neoplasms. <b>1990</b> , 76, 505-510		2
959	Future developments in IVF. <b>1990</b> , 46, 823-41		2
958	Simultaneous evaluation of epithelial cell function by CA 125 and stromal cell activity by aminoterminal propeptide of type III procollagen (PIIINP) in ovarian carcinoma. <b>1990</b> , 22, 115-21		16
957	The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. <b>1990</b> , 163, 1164-7		41
956	Predictive values of CA 125 antigen levels and CT scan in second-look procedures for ovarian cancer. <b>1990</b> , 37, 265-70		4
955	CA 125 in peritoneal fluid and serum from patients with benign gynecologic conditions and ovarian cancer. <b>1990</b> , 36, 161-5		27
954	Collagen metabolism in gynecologic patients: changes in the concentration of the aminoterminal propeptide of type III procollagen in serum. <b>1990</b> , 163, 1276-81		13

953	Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. <b>1991</b> , 165, 1356-1362	50
952	Role of embryonic factors in implantation: recent developments. <b>1991</b> , 5, 133-58	20
951	Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. <b>1991</b> , 165, 1356-62	62
950	Clinical applications of serum tumor markers. <b>1991</b> , 115, 623-38	152
949	Ultrasound in the diagnosis and treatment of ovarian cystic tumours. <i>Human Reproduction</i> , <b>1991</b> , 6, 177-85	12
948	First trimester CA 125 and Down's syndrome. <b>1991</b> , 98, 493-4	20
947	Raised serum CA 125 preceding the diagnosis of carcinoma of the fallopian tube: two case reports. <b>1991</b> , 98, 602-3	11
946	Enhancement of tumor-associated glycoprotein-72 antigen expression in hormone-related ovarian serous borderline tumors. <i>Cancer</i> , <b>1991</b> , 68, 348-54	6.4 8
945	Coordinate elevation of serum markers in ovarian cancer but not in benign disease. <i>Cancer</i> , <b>1991</b> , 68, 1758-63	6.4 52
944	The use of a panel of monoclonal antibodies can lower false-negative diagnoses of peritoneal washings in ovarian tumors. <i>Cancer</i> , <b>1991</b> , 68, 1803-7	6.4 9
943	First-trimester screening for fetal chromosomal abnormalities. Preliminary results. Dutch Working Party on Prenatal Diagnosis. <b>1991</b> , 11, 621-4	11
942	CA 125 serum levels in patients with non-neoplastic liver diseases. A clinical and laboratory study. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>1992</b> , 52, 201-6	2 30
941	Combined evaluation of serum CA 125 and CAM 29 in patients with epithelial ovarian cancer. <b>1992</b> , 13, 287-93	1
940	CA 125 concentrations in ovarian 'chocolate' cyst fluid can differentiate an endometriotic cyst from a cystic corpus luteum. <i>Human Reproduction</i> , <b>1992</b> , 7, 1314-7	5.7 41
939	What do CA 125 and other antigens tell us about ovarian cancer biology?. <b>1992</b> , 155, 85-93	11
938	Unsettled questions regarding ovarian cancer. <b>1992</b> , 155, 7-18	3
937	Peripheral CA 125 levels in patients with uterine fibroids. <i>Human Reproduction</i> , <b>1992</b> , 7, 35-8	5.7 23
936	CA-125 and placental protein 14 concentrations in plasma and peritoneal fluid of women with deeply infiltrating pelvic endometriosis**Presented in part at the 7th World Congress on Human Reproduction, Helsinki, Finland, June 26, 1990.***Supported by grant 9.0020.90 from the Belgian Fonds voor Wetenschappelijk Onderzoek, Brussels, Belgium, and by grants from the Academy of Finland and the Sigrid Juselius Foundation, Helsinki, Finland.. <b>1992</b> , 57, 523-530	103

935	CA-125 levels in human uterine fluid**Presented in part at the 46th Annual Meeting of The American Fertility Society, Washington, D.C., October 13 to 18, 1990.. <b>1992</b> , 57, 531-534	13
934	Endometrial and ovarian malignancies: epidemiology, etiology and prognostic factors. <b>1992</b> , 71, 331-6	2
933	Multiple serum marker assay in the diagnosis of endometriosis. <b>1992</b> , 6, 265-9	11
932	Prognostic significance of pretreatment serum levels of squamous cell carcinoma antigen and CA 125 in cervical carcinoma. <b>1992</b> , 28A, 1695-702	54
931	The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis. <b>1992</b> , 44, 147-54	98
930	The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients. <b>1992</b> , 44, 155-60	35
929	False-positive elevation of CA-125 in papillary serous carcinoma of the endometrium treated with postoperative whole abdominal radiation. <b>1992</b> , 47, 127-9	2
928	CA 125 measured before second-look laparotomy is an independent prognostic factor for survival in patients with epithelial ovarian cancer. <b>1992</b> , 45, 323-8	14
927	Early Diagnosis and Screening. <b>1992</b> , 6, 843-850	5
926	In Reply: Proportional Bias In the Microparticle Enzyme Assay (IMx) of Serum CA 125. <b>1992</b> , 38, 313-314	
925	Multicenter Technical and Clinical Evaluation of a Fully Automated Enzyme Immunoassay for CA 125. <b>1992</b> , 38, 1466-1471	18
924	Second-trimester cancer antigen 125 and Down's syndrome. <b>1992</b> , 12, 1062-6	11
923	Studies of a tumor-associated antigen, COX-1, recognized by a monoclonal antibody. <b>1992</b> , 35, 19-26	25
922	Lipoprotein(a) and CA125 levels in the plasma of patients with benign and malignant ovarian disease. <b>1992</b> , 52, 341-6	27
921	Screening in gynecologic cancers. <i>Cancer</i> , <b>1993</b> , 72, 1043-9	6.4 19
920	The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer. <i>International Journal of Gynecological Cancer</i> , <b>1993</b> , 3, 285-292	3.5 38
919	Evaluation of serum CA 125 level as a tumor marker in borderline tumors of the ovary. <i>International Journal of Gynecological Cancer</i> , <b>1993</b> , 3, 299-303	3.5 15
918	Serum CA 125 levels in patients with non-malignant liver diseases without ascites. <b>1993</b> , 71, 239	2

917	Maternal serum CA 125 levels in pregnancies with chromosomally-normal and -abnormal fetuses. Dutch Working Party on Prenatal Diagnosis. <b>1993</b> , 13, 1123-31	13
916	Relationship between serum CA 125 levels, endometrial thickness and corpus luteum function in different stages of ovarian activity. <b>1993</b> , 16, 175-9	10
915	Highly elevated serum CA 125 levels in a patient with cardiac failure. <b>1993</b> , 48, 71-3	10
914	Laparoscopic ovarian surgery. Panel discussion at the 21st annual meeting of the American Association of Gynecologic Laparoscopists (AAGL). September 25, 1992. <b>1993</b> , 1, 78-84	3
913	What do we know about the origin of CA 125?. <b>1993</b> , 49, 93-8	62
912	Discordant serum CA 125 values in commercial immunoassays. <b>1993</b> , 49, 99-103	14
911	Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. <b>1993</b> , 306, 1030-4	268
910	Prospective Study of Serum CA-125 Levels as Markers of Ovarian Cancer. <b>1993</b> , 269, 1123	45
909	CA 125 half-life in ovarian cancer: a multivariate survival analysis. <i>British Journal of Cancer</i> , <b>1993</b> , 67, 1368-7	44
908	Serum soluble interleukin-2 receptor assay in epithelial ovarian cancer. <b>1993</b> , 14, 303-9	7
907	Cancer-associated antigen CA 195 in patients with mucinous ovarian tumours: a comparative analysis with CEA, TATI and CA 125 in serum specimens and cyst fluids. <b>1993</b> , 14, 105-15	14
906	Purification and characterization of the CA 125 tumor-associated antigen from human ascites. <b>1993</b> , 14, 18-29	26
905	Effect of gynecological operations on the serum concentration of the aminoterminal propeptide of type III procollagen. <b>1993</b> , 72, 391-5	
904	On the Validity of Simultaneous Determinations of CA 125, SRA, and CA 72-4 in Patients Suffering from Ovarian Tumors. <b>1993</b> , 16, 199-203	
903	The effectiveness of ovarian cancer screening. A decision analysis model. <b>1993</b> , 118, 838-43	33
902	Women with a pelvic mass--when to perform an ultrasound. <b>1993</b> , 33, 404-7	5
901	Luminoimmunometric assay of tissue polypeptide antigen (TPA) and cancer antigen 125 (CA-125) in breast cancer patients. <b>1993</b> , 11, 83-90	
900	OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures. <b>1993</b> , 11, 1506-10	40

899	Heterologous double-determinant immunoradiometric assay CA 125 II: reliable second-generation immunoassay for determining CA 125 in serum. <b>1993</b> , 39, 2509-2513		55
898	Type-I and type-iii procollagen metabolites and ca 125 in epithelial ovarian-cancer. <b>1994</b> , 4, 669-74		
897	Screening in breast cancer families: is it useful?. <b>1994</b> , 26, 185-90		16
896	Hereditary ovarian carcinoma. <b>1994</b> , 10, 249-54		9
895	Evolution of screening for epithelial ovarian carcinoma: the quest for early diagnosis. <b>1994</b> , 10, 261-7		4
894	Serum CA 125 concentrations in patients with benign ovarian tumours. <b>1994</b> , 56, 71-4		23
893	Plasma D-dimer and peritoneal CA-125 levels as predictors of disease status in ovarian carcinoma. <b>1994</b> , 56, 168-71		7
892	Prognostic significance of serum CA 125 antigen assay in patients with non-small cell lung cancer. <i>Cancer</i> , <b>1994</b> , 73, 1368-76	6.4	24
891	Ovarian carcinoma. A review of the significance of familial risk factors and the role of prophylactic oophorectomy in cancer prevention. <i>Cancer</i> , <b>1994</b> , 74, 545-55	6.4	41
890	Diagnostic value of pelvic examination, ultrasound, and serum CA 125 in postmenopausal women with a pelvic mass. An international multicenter study. <i>Cancer</i> , <b>1994</b> , 74, 1398-406	6.4	72
889	Immunocytochemical and serological expression of CA 125: a clinicopathological study of 40 malignant ovarian epithelial tumours. <b>1994</b> , 24, 57-64		23
888	A Comparison of Ovarian Cyst Aspirate Cytology and Histology. The Case Against Aspiration of Cystic Pelvic Masses. <b>1994</b> , 34, 546-549		6
887	Biological markers and ovarian carcinomas: galactosyltransferase, CA 125, isoenzymes of amylase and alkaline phosphatase. <b>1994</b> , 227, 87-96		9
886	Performances analytiques d'un nouvel automate d'immunoanalyse : le LIA-mat S300. <b>1994</b> , 9, 181-187		
885	Evaluation of tumor-associated glycoprotein-72 and CA 125 serum markers in patients with gynecologic diseases. <b>1994</b> , 171, 1183-91		9
884	Adenocarcinoma of the submandibular gland with positive serum and tissue immunohistochemical staining for both CEA and CA 125: report of a case. <b>1994</b> , 108, 719-21		
883	Abstracts. <b>1994</b> , 12, 1-64		15
882	Highly elevated CA125 and tubo-ovarian abscess mimicking ovarian carcinoma. <b>1994</b> , 37, 143-4		8

881	Detection of a unique 32-kd protein in the peritoneal fluid of women with endometriosis*†Supported in part by grant HD21962 from the National Institutes of Health, Bethesda, Maryland.†Presented in part at the 48th Annual Meeting of The American Fertility Society, New Orleans, Louisiana, October 30 to November 5, 1992.. <b>1994</b> , 61, 288-293			14
880	Elevation of Cancer Antigen 125 in a Patient with Ascites. <b>1994</b> , 25, 146-147			
879	CA-125 levels in cervical mucus during the menstrual cycle. <b>1994</b> , 61, 843-9			10
878	Relationship between abnormally high levels of plasma CA 125 and resolution of acute pelvic pain in two women with endometrioma. <b>1995</b> , 40, 61-3			5
877	CA125 Serum levels in tuberculosis patients. <b>1995</b> , 10, 180-181			3
876	Serum CA-125 level in end-stage renal disease patients maintained on chronic peritoneal dialysis or hemodialysis: the effect of continuous presence of peritoneal fluid, peritonitis, and peritoneal catheter implantation. <b>1995</b> , 15, 468-72			16
875	The measurement of CA 125 and placental protein 14 in uterine flushings in women with recurrent miscarriage; relation to endometrial morphology. <i>Human Reproduction</i> , <b>1995</b> , 10, 2680-4	5.7		47
874	Clinical evaluation of CA-125 concentrations as a prognostic factor for pregnancy in infertile women with surgically treated endometriosis*†Presented in part at the International Meeting: CA-125 Ten Years Later, San Remo, Italy, October 10 to 13, 1993, and at the 50th annual meeting of The American Fertility Society, San Antonio, Texas, November 7 to 10, 1994.†Supported in part			33
873	Measurement of human chorionic gonadotropin-related immunoreactivity in serum, ascites and tumour cysts of patients with gynaecologic malignancies. <b>1995</b> , 25, 867-73			24
872	Early detection of ovarian cancer. <b>1995</b> , 45, 71-87			36
871	Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. <i>Cancer</i> , <b>1995</b> , 76, 2004-10	6.4		183
870	Ovarian cancer screening. <i>Cancer</i> , <b>1995</b> , 76, 2086-91	6.4		53
869	Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. <i>Cancer</i> , <b>1995</b> , 76, 2092-6	6.4		74
868	Molecular approaches to prevention and detection of epithelial ovarian cancer. <b>1995</b> , 23, 219-22			17
867	Involvement of ovarian factors magnified by pharmacological induction of multiple follicular development (MFD) in the increase in Ca125 occurring during the luteal phase and the first 12 weeks of induced pregnancies. <b>1995</b> , 12, 263-8			7
866	Superiority of CA 125 over CA 19-9 and CEA for epithelial ovarian malignancies. <b>1995</b> , 10, 23-28			3
865	Ovarian cancer screening. <b>1995</b> , 13, 783-93			28
864	Use of a new CA 125 assay in the diagnosis of endometriosis. <i>Human Reproduction</i> , <b>1995</b> , 10, 932-4	5.7		36

863	Früherkennung von Ovarialkarzinomen. <b>1995</b> , 18, 46-50	1
862	A comparison of laparotomy and laparoscopy in the management of ovarian masses. <b>1995</b> , 11, 19-25	9
861	The second generation CA 125 assays. <b>1995</b> , 27, 107-13	23
860	MEASUREMENT OF EPITHELIAL AND STROMAL CHANGES IN VULVAR CARCINOMA - A CLINICAL, BIOCHEMICAL AND IMMUNOHISTOCHEMICAL STUDY. <b>1995</b> , 7, 101	
859	CA125 and endometriosis. <b>1995</b> , 1, 173-87	33
858	Trans-vaginal ultrasound examination of ovarian masses in premenopausal women. <b>1995</b> , 62, 37-41	12
857	Correlations between periovulatory serum and follicular fluid CA-125 and granulosa cell hormones after controlled ovarian hyperstimulation. <b>1995</b> , 62, 95-9	2
856	Elevated serum ICTP concentrations reflect poor prognosis in patients with ovarian carcinoma. <b>1995</b> , 27, 57-61	7
855	Struma ovarii presenting as acute pseudo-Meigs syndrome with an elevated CA 125 level. <b>1996</b> , 36, 372-3	29
854	PET and [18F]-FDG in oncology: a clinical update. <b>1996</b> , 23, 717-35	220
853	Maternal serum CA 125 is of prognostic value in patients with uterine bleeding in the detection of small-for-gestational-age neonates. <b>1996</b> , 67, 143-7	3
852	Differential diagnosis of adnexal masses with transvaginal sonography, color flow imaging, and serum CA 125 assay in pre- and postmenopausal women. <b>1996</b> , 61, 68-72	44
851	Comparison of One First-Generation and Three Second-Generation Methods for the Determination of CA 125. <b>1996</b> , 11, 36-39	
850	CA 125 in seminal plasma: correlation with semen parameters. <i>Human Reproduction</i> , <b>1996</b> , 11, 574-8	5:7 3
849	The current role of laparoscopic surgery in gynecological oncology. <b>1996</b> , 14, 482-90	2
848	Colonic adenocarcinoma in a rhesus macaque ( <i>Macaca mulatta</i> ). <b>1996</b> , 25, 435-8	6
847	Circulating immunostimulatory protein 90K and soluble interleukin-2-receptor in human ovarian cancer. <b>1996</b> , 68, 34-8	29
846	ERBB2 and chromosome 17 centromere studies of ovarian cancer by fluorescence in situ hybridization. <b>1996</b> , 16, 130-7	18



845	CA125 expression at clinical diagnosis by ovarian carcinoma not detected through antecedent serum CA125 screening. <i>International Journal of Gynecological Cancer</i> , <b>1996</b> , 6, 98-101	3.5	
844	Elevated serum levels of macrophage colony-stimulating factor and OVX1, 11 months prior to the diagnosis of stage IC ovarian cancer. <i>International Journal of Gynecological Cancer</i> , <b>1996</b> , 6, 156-158	3.5	2
843	The impact of CA-125 on the sensitivity of abdominal/pelvic CT scan before second-look laparotomy in advanced ovarian carcinoma. <i>International Journal of Gynecological Cancer</i> , <b>1996</b> , 6, 213-218	3.5	4
842	Evaluations and Validations. <b>1997</b> , 35,		
841	Production of a single-chain fragment of the murine anti-idiotypic antibody ACA125 as phage-displayed and soluble antibody by recombinant phage antibody technique. <b>1997</b> , 16, 47-52		5
840	Control of differentiation, transformation, and apoptosis in granulosa cells by oncogenes, oncoviruses, and tumor suppressor genes. <b>1997</b> , 18, 435-61		100
839	Expression of cathepsin-D, CA125 and epidermal growth factor receptor in imprint smears of ovarian carcinoma. <b>1997</b> , 43, 125-30		3
838	Recommendations for Follow-up Care of Individuals With an Inherited Predisposition to Cancer. <b>1997</b> , 277, 997		499
837	Immunocytochemical localization of Cathepsin D and CA 125 in ovarian cancer. <b>1997</b> , 56, 31-7		3
836	Vaginal fluid and serum CEA, CA125 and SCC in normal conditions and in benign and malignant diseases of the genital tract. <b>1997</b> , 36, 755-9		7
835	Tumor Markers in Ovarian Malignancies. <b>1997</b> , 2, 324-329		27
834	The pituitary-gonadal function in postmenopausal women with epithelial ovarian tumors. <b>1997</b> , 105, 5-27		
833	Prelaparoscopic assessment of ovarian cysts in reproductive-age women. <b>1997</b> , 6, 157-167		7
832	Distribution of radiolabelled anti-CA125 monoclonal antibody OC125-F(ab)2-fragment following resection guided by antibodies (REGAJ) in ovarian cancer patients. <b>1997</b> , 11, 94-103		2
831	Immunohistochemical expression of inhibin/activin subunits in epithelial and granulosa cell tumours of the ovary. <b>1997</b> , 181, 413-8		44
830	Ovarian carcinogenesis and the biology of ovarian surface epithelium. <b>1997</b> , 173, 261-5		48
829	Complement-regulatory proteins in ovarian malignancies. <b>1997</b> , 70, 14-25		94
828	Isolation and characterization of ovarian cancer antigen CA 125 using a new monoclonal antibody (VK-8): identification as a mucin-type molecule. <b>1997</b> , 71, 842-50		73

827	Estimation of probability of malignancy using a logistic model combining physical examination, ultrasound, serum CA 125, and serum CA 72-4 in postmenopausal women with a pelvic mass: an international multicenter study. <b>1998</b> , 69, 56-63		34
826	Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with suspected ovarian cancer. <i>British Journal of Cancer</i> , <b>1998</b> , 77, 1870-4	8.7	52
825	Clinical utility of CA125 levels in predicting laparoscopically confirmed salpingitis in patients with clinically diagnosed pelvic inflammatory disease. <b>1998</b> , 6, 182-5		7
824	Laparoscopic management of ovarian tumors. <b>1998</b> , 12, 1326-33		24
823	Metaplastic changes in cultured human ovarian surface epithelium. <b>1998</b> , 34, 668-70		14
822	Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 3-1998. A 31-year-old woman with a pleural effusion, ascites, and persistent fever spikes. <b>1998</b> , 338, 248-54		17
821	A prospective randomized controlled study comparing the morphological and biochemical responses of the endometrium to two different forms of 'period-free' hormone replacement therapy. <i>Human Reproduction</i> , <b>1998</b> , 13, 2261-5	5.7	7
820	Explosive rise of serum CA 125 following the rupture of ovarian endometrioma. <i>Human Reproduction</i> , <b>1998</b> , 13, 3503-4	5.7	33
819	Bronchogenic cyst of the esophagus with high tumor marker levels--a case report and review of the literature. <b>1998</b> , 11, 130-3		19
818	CA 125: The past and the Future. <b>1998</b> , 13, 179-187		287
817	Clinical Utility of CA125 Levels in Predicting Laparoscopically Confirmed Salpingitis in Patients With Clinically Diagnosed Pelvic Inflammatory Disease. <b>1998</b> , 6, 182-185		5
816	More than 15 Years of CA 125: What is Known about the Antigen, Its Structure and Its Function. <b>1998</b> , 13, 188-195		55
815	CA 125 Production and Release by Ovarian Cancer Cells In Vitro. <b>1998</b> , 13, 200-206		19
814	Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women. <i>Cancer</i> , <b>1999</b> , 85, 2068-2072	6.4	16
813	Serum CA-125 values on the day of oocyte retrieval are not predictive of subsequent pregnancy with in-vitro fertilization. <i>Human Reproduction</i> , <b>1999</b> , 14, 1773-6	5.7	11
812	Cancer antigen 125: a sensitive marker of ascites in patients with liver cirrhosis. <b>1999</b> , 94, 1613-8		52
811	Metastasis to the breast from an ovarian carcinoma. <b>1999</b> , 78, 826-7		4
810	Prospectively detected cancer in familial breast/ovarian cancer screening. <b>1999</b> , 78, 906-911		4

809	CA125 and thyroglobulin staining in papillary carcinomas of thyroid and ovarian origin is not completely specific for site of origin. <b>1999</b> , 34, 113-7		17
808	Adenocarcinomas of various sites may exhibit immunoreactivity with anti-inhibin antibodies. <b>1999</b> , 35, 216-20		47
807	Ovarian cancer identified through screening with serum markers but not by pelvic imaging. <i>International Journal of Gynecological Cancer</i> , <b>1999</b> , 9, 497-501	3.5	13
806	Die Abklärung eines Adnaxbefundes. <b>1999</b> , 32, 467-484		1
805	Epithelial ovarian cancer: prevention, diagnosis, and treatment. <b>1999</b> , 49, 297-320		110
804	A comparison of methods for preoperative discrimination between malignant and benign adnexal masses: the development of a new logistic regression model. <b>1999</b> , 181, 57-65		127
803	Molecular methods for the diagnosis of cancer. <b>1999</b> , 1423, C11-8		10
802	Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women. <i>Cancer</i> , <b>1999</b> , 85, 2068-72	6.4	9
801	Expression of mucins and cytokeratins in ovarian cancer cell lines. <b>1999</b> , 145, 133-41		24
800	Case Reports. <b>1999</b> , 78, 826-830		6
799	Prospectively detected cancer in familial breast/ovarian cancer screening. <b>1999</b> , 78, 906-911		38
798	Gibt es prä- und intraoperative Kriterien zur Vermeidung des laparoskopischen Anoperierens von frühen Ovarialkarzinomen oder Borderline-Tumoren?. <b>1999</b> , 59, 1-4		
797	Reported Ovarian Cancer Screening Among a Population-Based Sample in Washington State. <b>2000</b> , 96, 70-74		2
796	The role of laparoscopy in the management of gynecologic malignancies. <b>2000</b> , 75, 60-71		2
795	Molecular approaches to management of epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , <b>2000</b> , 10, 2-7	3.5	10
794	Immunohistochemical evidence for mesothelial origin of paratesticular adenomatoid tumour. <b>2000</b> , 36, 109-15		67
793	Clinical outcome and tissue trauma after laparoscopic and abdominal hysterectomy:. <b>2000</b> , 79, 866-871		9
792	Chlamydia trachomatis seropositivity is associated both with stillbirth and preterm delivery. <b>2000</b> , 108, 584-8		45

791	Tuberculous peritonitis: part of the differential diagnosis in ovarian cancer. <b>2000</b> , 182, 740-2	46
790	Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. <b>2000</b> , 21, 2735-309S	704
789	Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. <b>2000</b> , 77, 454-9	115
788	Prognostic Value of CA125 Kinetics and Half-Life in Advanced Ovarian Cancer. <b>2000</b> , 15, 147-152	32
787	Clinical outcome and tissue trauma after laparoscopic and abdominal hysterectomy: a randomized controlled study. <b>2000</b> , 79, 866-871	57
786	An application of artificial neural networks in ovarian cancer early detection. <b>2000</b> ,	3
785	Diagnostische Wertigkeit von Sonographie, Kernspintomographie und Positronenemissionstomographie zur Beurteilung der Dignität von Adnextumoren bei prämenopausalen Patientinnen - Premenopausal Adnex Masses: Diagnostic Accuracy of Sonography, Magnetic Resonance Imaging, and Positron Emission Tomography -. <b>2000</b> , 60, 544-552	
784	Recent advances in immunohistochemistry in the diagnosis of ovarian neoplasms. <b>2000</b> , 53, 327-34	61
783	How CA 125 is used in routine clinical practice. <b>2000</b> , 36, 1933-7	15
782	Reported ovarian cancer screening among a population-based sample in Washington state. <b>2000</b> , 96, 70-4	12
781	The Management of Women at High Risk of Experiencing Hereditary Breast and Ovarian Cancer. <b>2000</b> , 7, 201-215	3
780	Re. Zuckerman et al. Sensitivity of Ca-125 in patients with liver cirrhosis in the presence of ascites. <b>2001</b> , 96, 253-254	
779	Clinical uses of tumor markers: a critical review. <b>2001</b> , 38, 225-62	97
778	Caracterización preoperatoria de las tumoraciones de ovario mediante ecografía, Doppler y determinación sérica de CA125. Estudio comparativo. <b>2001</b> , 44, 205-215	
777	Ovarian cancer and ovarian masses. <b>2001</b> , 333-340	
776	Dialysate Cancer Antigen 125 Concentration as Marker of Peritoneal Membrane Status in Patients Treated with Chronic Peritoneal Dialysis. <b>2001</b> , 21, 560-567	95
775	Serum Tumor Markers: Past, State of the Art, and Future. <b>2001</b> , 16, 73-86	22
774	Ovarian cancer screening: are we making any progress?. <b>2001</b> , 13, 399-402	33

773	Familial ovarian cancer and early ovarian cancer: biologic, pathologic, and clinical features. <b>2001</b> , 20, 48-63	33
772	Application of tumor markers in ovarian malignancies. <b>2001</b> , 16, 224-33	5
771	Monoclonal antibody SM047 as an immunohistochemical marker of ovarian adenocarcinoma. <b>2001</b> , 38, 542-9	4
770	OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. <i>Cancer</i> , <b>2001</b> , 92, 2837-44	6.4 81
769	Screening for the major malignancies affecting women: current guidelines. <b>2001</b> , 184, 1021-30	34
768	Preoperative diagnosis of ovarian tumors with MR imaging: comparison with transvaginal sonography, positron emission tomography, and histologic findings. <b>2001</b> , 177, 123-9	154
767	The CA 125 gene: an extracellular superstructure dominated by repeat sequences. <b>2001</b> , 22, 348-66	223
766	Re. Zuckerman et al.--Sensitivity of CA-125 in patients with liver cirrhosis in the presence of ascites. <b>2001</b> , 96, 253-4	16
765	Absence of toxicity of ornidazole after a 10-yr continuous daily use for Crohn's disease. <b>2001</b> , 96, 254-5	3
764	Chapter 23. Tumor classification for tailored cancer therapy. <b>2002</b> , 37, 225-236	
763	Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. <b>2002</b> , 223, 780-8	166
762	Usefulness of CA19-9 versus CA125 for the diagnosis of endometriosis. <b>2002</b> , 78, 733-9	82
761	Ovarian Cancer. <i>Cancer Treatment and Research</i> , <b>2002</b> ,	3.5 1
760	Homeobox gene expression in ovarian cancer. <i>Cancer Treatment and Research</i> , <b>2002</b> , 107, 231-45	3.5 3
759	Preoperative CA-125 levels in patients with hereditary compared to sporadic epithelial ovarian carcinoma. <b>2002</b> , 84, 413-5	3
758	The search for predictive patterns in ovarian cancer: proteomics meets bioinformatics. <b>2002</b> , 1, 111-2	27
757	Ovarian cancer screening. <b>2002</b> , 63, 210-3	8
756	The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass. <b>2002</b> , 187, 385-92	28

755	P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis. <b>2002</b> , 110, 545-53		25
754	Use of CA-125 and ultrasound in high-risk women. <i>International Journal of Gynecological Cancer</i> , <b>2002</b> , 12, 86-91	3.5	35
753	Early events in ovarian epithelial carcinogenesis: progress and problems in experimental approaches. <i>International Journal of Gynecological Cancer</i> , <b>2002</b> , 12, 691-703	3.5	66
752	Gene expression in epithelial ovarian carcinoma. <b>2002</b> , 21, 6289-98		83
751	Specific keynote: ovarian cancer risk assessment and the potential for early detection. <b>2003</b> , 88, S75-9; discussion S80-3		16
750	Tuberculous peritonitis mimicking peritonitis carcinomatosis: a case report. <b>2003</b> , 162, 853-5		15
749	Ovarian cancer and high-risk women-implications for prevention, screening, and early detection. <b>2003</b> , 91, 15-31		52
748	Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. <i>Cancer</i> , <b>2003</b> , 98, 66-73	6.4	96
747	Quantitative analysis of acyl-lysophosphatidic acid in plasma using negative ionization tandem mass spectrometry. <b>2003</b> , 788, 85-92		55
746	CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , <b>2003</b> , 13, 120-4	3.5	85
745	Inhibins and activins: clinical advances in reproductive medicine. <b>2003</b> , 58, 115-27		24
744	Translational research in ovarian cancer: a must. <i>International Journal of Gynecological Cancer</i> , <b>2003</b> , 13 Suppl 2, 220-30	3.5	5
743	Proteomic analysis for early detection of ovarian cancer: a realistic approach?. <i>International Journal of Gynecological Cancer</i> , <b>2003</b> , 13 Suppl 2, 133-9	3.5	30
742	[Clinical utility of serous tumoural markers]. <b>2003</b> , 32, 227-39		2
741	Ovarian cancer screening. <b>2003</b> , 17, 989-1005, ix		47
740	Stellenwert der systemischen Chemotherapie beim Granulosazelltumor des Ovars: Eine Langzeitanalyse von 25 Patientinnen. <b>2003</b> , 63, 529-537		2
739	Stellenwert der systemischen Chemotherapie beim Granulosazelltumor des Ovars: Eine Langzeitanalyse von 25 Patientinnen. <b>2003</b> , 24, 127-135		
738	Proteomic analysis for early detection of ovarian cancer: A realistic approach?. <i>International Journal of Gynecological Cancer</i> , <b>2003</b> , 13, 133-139	3.5	22

737	Cancer screening: how good is good enough?. <b>2004</b> , 22, 4037-9	11
736	Molecular markers for early detection of renal carcinoma: investigative approach. <b>2004</b> , 10, 6296S-301S	21
735	Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. <b>2004</b> , 22, 4059-66	140
734	Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level. <b>2004</b> , 57, 153-6	39
733	Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. <b>2004</b> , 64, 5882-90	796
732	Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. <b>2004</b> , 10, 3919-26	106
731	The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma. <b>2004</b> , 93, 131-6	37
730	The use of mathematical models to evaluate pelvic masses; can they beat an expert operator?. <b>2004</b> , 18, 91-104	72
729	Ovarian Carcinogenesis. <b>2004</b> , 591-612	5
728	Laparoscopic management of ovarian cysts. <b>2004</b> , 31, 581-92, ix	10
727	Serum tumor markers in the management of ovarian, endometrial and cervical cancer. <b>2004</b> , 58, 24-38	133
726	Diagnostic usefulness of carbohydrate antigen-125 in cancerous and noncancerous peritoneal effusions. <b>2005</b> , 205, 11-8	5
725	Predictors of suboptimal surgical cytoreduction in women treated with initial cytoreductive surgery for advanced stage epithelial ovarian cancer. <b>2005</b> , 193, 568-74; discussion 574-6	24
724	Management of adnexal masses in postmenopausal women. <b>2005</b> , 193, 30-5	30
723	CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. <i>International Journal of Gynecological Cancer</i> , <b>2005</b> , 15, 679-91	3.5 214
722	Efficient screening for ovarian cancers using a combination of tumor markers CA602 and CA546. <i>International Journal of Gynecological Cancer</i> , <b>2005</b> , 15, 37-44	3.5 8
721	Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis. <b>2005</b> , 96, 516-9	49
720	Potential markers that complement expression of CA125 in epithelial ovarian cancer. <b>2005</b> , 99, 267-77	279

719	Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use. <b>2005</b> , 99, 462-71		32
718	Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2005</b> , 14, 981-7	4	220
717	Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2005</b> , 14, 306-18	4	47
716	Immunohistochemical Validation of B7-H4 (DD-O110) as a Biomarker of Ovarian Cancer: Correlation with CA-125. <b>2005</b> , 4, 499-503		
715	Immunocytochemistry. <b>2005</b> , 555-571		
714	Greatly Elevated Serum CA-125 Level in a Patient with a Ruptured Endometrioma. <b>2005</b> , 21, 117-120		2
713	Epitomics: serum screening for the early detection of cancer on microarrays using complex panels of tumor antigens. <b>2005</b> , 5, 735-43		34
712	Comparative gene expression analysis of ovarian carcinoma and normal ovarian epithelium by serial analysis of gene expression. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2005</b> , 14, 1717-23	4	53
711	Tumor necrosis factor-alpha-related intraperitoneal release of CA 125 in cirrhotic patients with sterile ascites. <b>2005</b> , 51, 2207-8		8
710	Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study. <b>2005</b> , 23, 5938-42		58
709	Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. <b>2005</b> , 23, 9338-43		111
708	Do levels of serum cancer antigen 125 and creatine kinase predict the outcome in pregnancies of unknown location?. <i>Human Reproduction</i> , <b>2005</b> , 20, 3348-54	5.7	32
707	Medical Biomethods Handbook. <b>2005</b> ,		2
706	Genetic Counseling for Patients with Breast Cancer and Their Families. <b>2005</b> , 319-330		
705	The development of a mouse model of ovarian endosalpingiosis. <b>2005</b> , 146, 5228-36		45
704	Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer. <b>2006</b> , 5, 1626-35		194
703	The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma. <b>2006</b> , 32, 588-91		15
702	Ovarian Cancer Screening. 47-68		0



701	Laparoscopic management of the adnexal mass. <b>2006</b> , 49, 535-48	49
700	The incidental postmenopausal adnexal mass. <b>2006</b> , 49, 506-16	47
699	Screening for ovarian cancer. <b>2006</b> , 49, 433-47	65
698	Diagnosis and management of epithelial ovarian cancer. <b>2006</b> , 107, 1399-410	150
697	Evaluation of plasma lysophospholipids for diagnostic significance using electrospray ionization mass spectrometry (ESI-MS) analyses. <b>2000</b> , 905, 242-59	131
696	Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer. <b>2006</b> , 100, 247-53	35
695	Elevated serum RANTES levels in patients with ovarian cancer correlate with the extent of the disorder. <b>2006</b> , 102, 542-5	45
694	Regulation of mucin expression: mechanistic aspects and implications for cancer and inflammatory diseases. <b>2006</b> , 1765, 189-222	119
693	Screening for ovarian cancer in the general population. <b>2006</b> , 20, 307-20	33
692	Multiple biomarker panels for early detection of ovarian cancer. <b>2006</b> , 2, 733-41	33
691	Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection. <b>2006</b> , 66, 1792-8	31
690	Le dépistage du cancer ovarien. <b>2006</b> , 127-142	
689	Endoscope-assisted thoracoscopic technique for esophageal bronchogenic cyst which presented elevated CA125. <b>2006</b> , 23, 209-14	13
688	Screening for ovarian cancer: progress and challenges. <b>2006</b> , 32, 173-5	
687	B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. <b>2006</b> , 66, 1570-5	144
686	Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125. <b>2007</b> , 99, 1706-14	150
685	Preoperative predictors for residual tumor after surgery in patients with ovarian carcinoma. <b>2007</b> , 72, 293-301	20
684	Hereditary Breast Cancer. <b>2007</b> ,	

683	Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma. <b>2007</b> , 13, 4422-8		33
682	Common gynecologic problems in geriatric-aged women. <b>2007</b> , 50, 687-708		6
681	Carcinomas of ovary and lung with clear cell features: can immunohistochemistry help in differential diagnosis?. <b>2007</b> , 26, 134-40		18
680	Update on ovarian cancer screening. <b>2007</b> , 19, 22-6		32
679	Differential expression of ABCF2 protein among different histologic types of epithelial ovarian cancer and in clear cell adenocarcinomas of different organs. <b>2007</b> , 38, 134-9		21
678	Tumor markers in biological fluids associated with pregnancy. <b>2007</b> , 44, 151-78		95
677	Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature. <i>International Journal of Gynecological Cancer</i> , <b>2007</b> , 17, 21-31	3-5	94
676	CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study. <b>2007</b> , 104, 508-15		90
675	Metastatic colorectal adenocarcinoma involving the ovary with elevated serum CA125: a potential diagnostic pitfall. <b>2007</b> , 105, 395-8		14
674	Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. <b>2007</b> , 106, 112-8		90
673	Biochemical prognostic factors and risk of relapses in patients with cervical cancer. <b>2007</b> , 107, S23-6		28
672	Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. <b>2007</b> , 107, 526-31		80
671	Radiological staging of ovarian cancer: imaging findings and contribution of CT and MRI. <b>2007</b> , 17, 3223-35		74
670	The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. <b>2008</b> , 66, 10-20		109
669	Ovarian cancer proteomics: Many technologies one goal. <b>2008</b> , 2, 195-218		8
668	National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. <b>2008</b> , 54, e11-79		45 <sup>1</sup>
667	Imaging of gynecological disease (3): clinical and ultrasound characteristics of granulosa cell tumors of the ovary. <b>2008</b> , 31, 450-6		60
666	Antigen-specific immunotherapy of cervical and ovarian cancer. <b>2008</b> , 222, 43-69		54

665	Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it?. <b>2008</b> , 111, 179-87		32
664	Serum markers in the diagnosis of tubal pregnancy. <b>2008</b> , 63, 701-8		12
663	Preoperative serum thrombopoietin levels are higher in patients with ovarian cancer than with benign cysts. <b>2008</b> , 140, 67-70		3
662	Rules of tumor cell development and their application to biomarkers for ovarian cancer. <b>2008</b> , 35, 403-9		5
661	Early detection of ovarian cancer. <b>2008</b> , 2, 291-303		57
660	In Reply. <b>2008</b> , 26, 513-513		5
659	Proteomic contributions to personalized cancer care. <b>2008</b> , 7, 1780-94		77
658	Cancer antigen 125 and prognosis. <b>2008</b> , 20, 4-8		51
657	Surgery in Pregnancy. 393-454		
656	Ovarian cancer and masses. 187-192		
655	Gastrointestinal stromal tumor in pregnancy: a case report. <b>2009</b> , 2009, 456402		12
654	Clinical utility of CA-125 for maintenance therapy in the treatment of advanced stage ovarian carcinoma. <i>International Journal of Gynecological Cancer</i> , <b>2009</b> , 19, 239-41	3.5	12
653	Circulating TAAs: Biomarkers for Cancer Diagnosis, CA125. 261-279		
652	Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers. <b>2009</b> , 8, 661-9		88
651	Meigs' Syndrome with Elevated Serum CA125: Case Report and Review of the Literature. <b>2009</b> , 2, 61-66		22
650	Immunology of gynecologic neoplasms: analysis of the prognostic significance of the immune status. <b>2009</b> , 9, 541-65		14
649	A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. <b>2009</b> , 112, 40-6		557
648	Urinary levels of Bcl-2 are elevated in ovarian cancer patients. <b>2009</b> , 112, 60-7		28

647	Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors. <b>2009</b> , 113, 221-7			11
646	A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172. <b>2009</b> , 115, 81-85			20
645	Genomic and proteomic biomarkers for cancer: a multitude of opportunities. <b>2009</b> , 1796, 176-93			48
644	Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?. <b>2009</b> , 124, 919-23			100
643	The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study. <i>Cancer</i> , <b>2009</b> , 115, 1028-35	6.4		68
642	Mucins in ovarian cancer diagnosis and therapy. <b>2009</b> , 2, 21			40
641	Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review. <b>2009</b> , 142, 99-105			84
640	Managing hereditary ovarian cancer. <b>2009</b> , 64, 172-6			16
639	Laparoscopy and ovarian cancer: a paradigm change in the management of ovarian cancer?. <b>2009</b> , 16, 250-62			39
638	Different altered stage correlative expression of high abundance acute-phase proteins in sera of patients with epithelial ovarian carcinoma. <i>Journal of Hematology and Oncology</i> , <b>2009</b> , 2, 37	22.4		9
637	Oncology Biomarkers. <b>2009</b> ,			
636	Clinical practice. Screening for ovarian cancer. <b>2009</b> , 361, 170-7			269
635	Differential methylation profile of ovarian cancer in tissues and plasma. <b>2009</b> , 11, 60-65			71
634	Predicting the response of advanced cervical and ovarian tumors to therapy. <b>2009</b> , 64, 548-60			15
633	Preoperative CA-125 levels in 123 patients with borderline ovarian tumors: a retrospective analysis and review of the literature. <i>International Journal of Gynecological Cancer</i> , <b>2009</b> , 19, 1335-8	3.5		20
632	Are surveillance procedures of clinical benefit for patients treated for ovarian cancer?: A retrospective Italian multicentric study. <i>International Journal of Gynecological Cancer</i> , <b>2009</b> , 19, 367-74	3.5		56
631	Prognostic value of CA 125 in ovarian cyst fluid of patients with epithelial ovarian cancer. <b>2009</b> , 23,			
630	Gene expression profiling reveals differentially expressed genes in ovarian cancer of the hen: support for oviductal origin?. <b>2010</b> , 1, 177-86			32

629	Pelvic mass associated with raised CA 125 for benign condition: a case report. <b>2010</b> , 8, 28		13
628	Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. <b>2010</b> , 203, 228.e1-6		173
627	CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease. <i>Cancer</i> , <b>2010</b> , 116, 2850-3	6.4	46
626	Nidogen-2: a new serum biomarker for ovarian cancer. <b>2010</b> , 43, 355-61		26
625	Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. <i>British Journal of Cancer</i> , <b>2010</b> , 103, 693-700	8.7	157
624	Ovarian cancer pathogenesis: a model in evolution. <b>2010</b> , 2010, 932371		168
623	Serum biomarkers for early detection of gynecologic cancers. <b>2010</b> , 2, 1312-27		27
622	Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype. <b>2010</b> , 63, 169-73		44
621	The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor. <b>2010</b> , 17, 929-40		80
620	Stress-induced phosphoprotein 1 as a secreted biomarker for human ovarian cancer promotes cancer cell proliferation. <b>2010</b> , 9, 1873-84		87
619	Why the Medical Research Council refused Robert Edwards and Patrick Steptoe support for research on human conception in 1971. <i>Human Reproduction</i> , <b>2010</b> , 25, 2157-74	5.7	56
618	Diagnosing epithelial ovarian cancer: can we detect it earlier?. <b>2010</b> , 2, 15-20		
617	Clinical decision making using ovarian cancer risk assessment. <b>2010</b> , 194, 337-42		10
616	Ovarian cancer biomarker screening: still too early to tell. <b>2010</b> , 6, 487-90		9
615	Incidental adnexal masses detected at low-dose unenhanced CT in asymptomatic women age 50 and older: implications for clinical management and ovarian cancer screening. <b>2010</b> , 257, 144-50		53
614	Combinatorial peptide libraries facilitate development of multiple reaction monitoring assays for low-abundance proteins. <b>2010</b> , 9, 1236-45		51
613	The Clinical Impact of Computed Tomography Immediately Following Primary Chemotherapy in Patients With Epithelial Ovarian Cancer. <b>2010</b> , 3, 52-55		
612	Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms. <b>2010</b> , 296, 43-8		71

611	FTwo novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma. <b>2011</b> , 5, 227-240	30
610	Prognostic biomarkers in ovarian cancer. <b>2010</b> , 8, 231-51	25
609	[Interest of CA 125 level in management of ovarian cancer]. <b>2011</b> , 39, 296-301	11
608	Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer. <b>2011</b> , 158, 338-42	29
607	Meigs' syndrome with elevated serum cancer antigen 125 levels in a case of ovarian sclerosing stromal tumor. <b>2011</b> , 50, 196-200	25
606	Robert Edwards: the path to IVF. <b>2011</b> , 23, 245-62	45
605	Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients. <i>International Journal of Gynecological Cancer</i> , <b>2011</b> , 21, 1040-7	3.5 40
604	Adding cancer antigen 125 screening to gray scale sonography for predicting specific diagnosis of benign adnexal masses in premenopausal women: is it worthwhile?. <b>2011</b> , 30, 1381-6	8
603	The management of anxiety and knowledge of serum CA-125 after an ovarian cancer diagnosis. <b>2011</b> , 15, 625-32	7
602	Screening for ovarian cancer: old tools, new lessons. <b>2010</b> , 8, 177-86	7
601	A review of cost-effectiveness studies in ovarian cancer. <b>2011</b> , 18, 59-64	26
600	Committee Opinion No. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. <b>2011</b> , 117, 742-746	100
599	Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. <b>2011</b> , 117, 1289-1297	162
598	[Management of hereditary ovarian cancer]. <b>2011</b> , 152, 1596-608	2
597	Comparison of candidate serologic markers for type I and type II ovarian cancer. <b>2011</b> , 122, 560-6	41
596	Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. <b>2011</b> , 122, 548-53	61
595	Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels. <b>2011</b> , 123, 295-300	36
594	Il carcinoma ovarico: nuove acquisizioni sulla patogenesi e nella diagnostica di laboratorio. <b>2011</b> , 7, 195-204	

593	Solid phase immunoradiometric assay for CA125 antigen levels in blood using monoclonal antibodies. <b>2011</b> , 288, 31-36		3
592	Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer. <b>2011</b> , 60, 975-84		38
591	Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer. <b>2011</b> , 32, 831-8		23
590	Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction. <i>Cancer</i> , <b>2011</b> , 117, 545-53	6.4	24
589	Induction of cytotoxic T lymphocytes against ovarian cancer-initiating cells. <b>2011</b> , 129, 1990-2001		37
588	A MEMS ultrasonic sensor design for early detection of ovarian cancer. <b>2011</b> ,		1
587	ROMA or death: advances in epithelial ovarian cancer diagnosis. <b>2011</b> , 49, 443-5		5
586	Nobel Prizes in medicine: are clinicians out of fashion?. <b>2011</b> , 104, 387-9		6
585	The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses. <b>2011</b> , 49, 2081-8		48
584	Performance of the American College of Obstetricians and Gynecologists' ovarian tumor referral guidelines with a multivariate index assay. <b>2011</b> , 117, 1298-1306		61
583	A novel approach to predict the likelihood of specific ovarian tumor pathology based on serum CA-125: a multicenter observational study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2011</b> , 20, 2420-8	4	23
582	Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. <i>Cancer Prevention Research</i> , <b>2011</b> , 4, 1401-8	3.2	42
581	An Atlas of Gynecologic Oncology. <b>2011</b> ,		1
580	Risk of malignancy in sonographically confirmed ovarian tumors. <b>2012</b> , 55, 52-64		12
579	Epigenetic biomarkers in the diagnosis of ovarian cancer. <b>2012</b> , 6, 421-38		6
578	Application of positron emission tomography in gynecological malignancies. <b>2012</b> , 27, 150-162		
577	Biomarkers for screening, diagnosis, and monitoring of ovarian cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2012</b> , 21, 1902-12	4	67
576	Prise en charge des masses annexielles pendant la grossesse. <b>2012</b> , 7, 1-9		1

575	Ovarian cancer screening: development of the risk of ovarian cancer algorithm (ROCA) and ROCA screening trials. <i>International Journal of Gynecological Cancer</i> , <b>2012</b> , 22 Suppl 1, S24-6	3.5	49
574	Using a multivariate index assay to assess malignancy in a pelvic mass. <b>2012</b> , 119, 365-7		0
573	Anticancer immune reactivity and long-term survival after treatment of metastatic ovarian cancer with dendritic cells. <b>2012</b> , 3, 66-74		7
572	Multiplexed bead-based immunoassay of four serum biomarkers for diagnosis of ovarian cancer. <b>2012</b> , 28, 585-91		12
571	Does HE4 have a role as biomarker in the recurrence of ovarian cancer?. <b>2012</b> , 33, 2117-23		51
570	A urinary Bcl-2 surface acoustic wave biosensor for early ovarian cancer detection. <b>2012</b> , 12, 7423-37		23
569	Human epididymis protein 4 (HE4) in benign and malignant diseases. <b>2012</b> , 50, 2181-8		51
568	Protein biomarkers of ovarian cancer: the forest and the trees. <b>2012</b> , 8, 55-71		59
567	Diffuse peritoneal chlamydial infection presenting as possible ovarian peritoneal carcinomatosis in an adolescent female. <b>2012</b> , 50, 531-3		4
566	Ruptured ovarian endometrioma with an extreme rise in serum CA 125 level - A case report: Ovarian endometrioma with very high CA-125 level. <b>2012</b> , 2, 100-1		3
565	Ovarian cancer: role of ultrasound in preoperative diagnosis and population screening. <b>2012</b> , 40, 245-54		13
564	Performance of a multianalyte test as an aid for the diagnosis of ovarian cancer in symptomatic women. <b>2012</b> , 10, 45		13
563	Identification of quiescent, stem-like cells in the distal female reproductive tract. <b>2012</b> , 7, e40691		50
562	Identification and confirmation of differentially expressed fucosylated glycoproteins in the serum of ovarian cancer patients using a lectin array and LC-MS/MS. <b>2012</b> , 11, 4541-52		80
561	Development of multiplexed bead-based immunoassays for the detection of early stage ovarian cancer using a combination of serum biomarkers. <b>2012</b> , 7, e44960		42
560	Two Unusual Clinical Presentations of Broad-Ligament Leiomyomas: A Report of Two Cases. <b>2012</b> , 48, 23		0
559	Extremely elevated CA-125 in benign ovarian disease due to stretch of the peritoneum. <b>2012</b> , 2012,		3
558	A comparison of the cyclic variation in serum levels of CA125 across the menstrual cycle using two commercial assays. <b>2012</b> , 14, 250-6		12



557	Health economics of screening for gynaecological cancers. <b>2012</b> , 26, 163-73	2
556	Screening for ovarian cancer in the general population. <b>2012</b> , 26, 243-56	36
555	Value of FDG PET/CT in patients with treated ovarian cancer and raised CA125 serum levels. <b>2012</b> , 14, 123-9	34
554	The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors. <b>2013</b> , 6, 45	41
553	Differential Diagnosis of Borderline Ovarian Tumors from Stage I Malignant Ovarian Tumors using FDG PET/CT. <b>2013</b> , 47, 81-8	16
552	Surface Epithelial-Stromal Tumors of the OvaryOpen image in new window. <b>2013</b> , 107-248	1
551	Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies. <b>2013</b> , 12, 5383-94	86
550	Human epididymis protein 4 in cancer diagnostics: a promising and reliable tumor marker. <b>2013</b> , 59, 1-21	24
549	Breast and Gynecological Cancers. <b>2013</b> ,	5
548	Investigating the clinical potential for 14-3-3 zeta protein to serve as a biomarker for epithelial ovarian cancer. <b>2013</b> , 6, 79	9
547	Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta-analysis. <b>2013</b> , 167, 81-5	58
546	Utility of progranulin and serum leukocyte protease inhibitor as diagnostic and prognostic biomarkers in ovarian cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2013</b> , 22, 1730-5	4 28
545	The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass. <b>2013</b> , 128, 239-44	60
544	Tratamiento de las masas anexiales durante el embarazo. <b>2013</b> , 49, 1-10	
543	Role of osteopontin in differential diagnosis of ovarian tumors. <b>2013</b> , 39, 1518-25	12
542	Immunohistological analysis of stress-induced phosphoprotein 1 in ovarian cancer patients with low serum cancer antigen 125 levels. <b>2013</b> , 52, 185-91	9
541	Identification of multiple novel protein biomarkers shed by human serous ovarian tumors into the blood of immunocompromised mice and verified in patient sera. <b>2013</b> , 8, e60129	15
540	Quantitative analysis of serum IgG galactosylation assists differential diagnosis of ovarian cancer. <b>2013</b> , 12, 4046-55	45

539	S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013. <b>2013</b> , 73, 874-889	34
538	Comparison of the Diagnostic Performances of CA125 and Multiple Marker Combinations for Early Diagnosis of Ovarian Cancer. <b>2013</b> , 5, 141-150	3
537	High impact of FDG-PET/CT in diagnostic strategies for ovarian cancer. <b>2013</b> , 54, 340-8	15
536	The predictive value of risk of malignancy index calculation in adnexal masses. <b>2013</b> , 4,	
535	Screening for gynecological cancers. <b>2013</b> , 8, 143-160	1
534	In reply. <b>2013</b> , 122, 1114	
533	What is new in gynecologic oncology? Thought-provoking articles from the past year. <b>2013</b> , 122, 393-394	
532	Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. <b>2013</b> , 122, 1114	2
531	Clinical efficacy of serum human epididymis protein 4 as a diagnostic biomarker of ovarian cancer: A pilot study. <b>2013</b> , 56, 234-41	9
530	Clinical significance of serum CA-125 in Korean females with ascites. <b>2013</b> , 54, 1241-7	5
529	Tumor stress-induced phosphoprotein1 (STIP1) as a prognostic biomarker in ovarian cancer. <b>2013</b> , 8, e57084	43
528	Pretreatment CA 15-3 Levels do not Predict Disease-Free Survival in Patients with Advanced Epithelial Ovarian Cancer. <b>2013</b> , 99, 257-260	
527	Gemcitabine-based regimen for primary ovarian angiosarcoma with MYC amplification. <b>2014</b> , 21, e782-9	4
526	The expression of FAS-associated factor 1 and heat shock protein 70 in ovarian cancer. <b>2014</b> , 57, 281-90	12
525	The Use of Risk of Malignancy Index for Adnexal Masses. <b>2014</b> , 04,	0
524	Ovarian Cancer Biomarkers. <b>2014</b> , 25-77	19
523	Correlation of cytohistological expression and serum level of ca125 in ovarian neoplasm. <b>2014</b> , 8, 41-3	2
522	Quantification of the concentration gradient of biomarkers between ovarian carcinoma interstitial fluid and blood. <b>2014</b> , 2, 18-23	9

521	The serum glycome to discriminate between early-stage epithelial ovarian cancer and benign ovarian diseases. <b>2014</b> , 2014, 238197	21
520	Can CA-125 predict lymph node metastasis in epithelial ovarian cancers in Turkish population?. <b>2014</b> , 2014, 492537	2
519	Severe adenomyosis and CA125. <b>2014</b> , 34, 79-81	18
518	Serum microRNAs in clear cell carcinoma of the ovary. <b>2014</b> , 53, 536-41	22
517	Risk-reducing surgery for women at high risk of epithelial ovarian cancer. <b>2014</b> , 16, 185-191	6
516	Mutational analysis of FOXL2 p.C134W and expression of bone morphogenetic protein 2 in Japanese patients with granulosa cell tumor of ovary. <b>2014</b> , 40, 1197-204	8
515	Humoral autoimmune responses to insulin-like growth factor II mRNA-binding proteins IMP1 and p62/IMP2 in ovarian cancer. <b>2014</b> , 2014, 326593	11
514	Multiple MAGE-A genes as surveillance marker for the detection of circulating tumor cells in patients with ovarian cancer. <b>2014</b> , 19, 34-42	25
513	Serum cytokeratin-19 fragment (Cyfra 21-1) is a prognostic indicator for epithelial ovarian cancer. <b>2014</b> , 53, 30-4	11
512	Advances in Diagnosis and Management of Ovarian Cancer. <b>2014</b> ,	2
511	Wnt/ $\beta$ -catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer. <b>2014</b> , 7, 16	57
510	HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer. <b>2014</b> , 35, 7249-58	33
509	Clinical performance of a multivariate index assay for detecting early-stage ovarian cancer. <b>2014</b> , 210, 78.e1-9	30
508	DNA methylation markers for early detection of women's cancer: promise and challenges. <b>2014</b> , 6, 311-27	61
507	Evaluation of biodegradable microspheres containing nomegestrol acetate in a rat model of endometriosis. <b>2014</b> , 65, 15-20	5
506	The effect of ovarian imaging on the clinical interpretation of a multivariate index assay. <b>2014</b> , 211, 65.e1-65.e11	11
505	A predictive model combining human epididymal protein 4 and radiologic features for the diagnosis of ovarian cancer. <b>2014</b> , 132, 573-7	18
504	The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group study. <b>2014</b> , 132, 560-5	39

503	In 2014, can we do better than CA125 in the early detection of ovarian cancer?. <b>2014</b> , 5, 286-300	48
502	Comparison of HE4, CA125, and ROMA Diagnostic Accuracy: A Prospective and Multicenter Study for Chinese Women With Epithelial Ovarian Cancer. <b>2015</b> , 94, e2402	13
501	Ovary preservation in the treatment of childhood Meigs syndrome. <b>2015</b> , 62, 2011-4	3
500	CA 19-9 in evaluation of adnexal mass: retrospective cohort analysis and review of the literature. <b>2015</b> , 30, e333-40	8
499	Review of Commonly Used Serum Tumor Markers and Their Relevance for Image Interpretation. <b>2015</b> , 39, 825-34	16
498	Inhibition of autophagy in peripheral blood mononuclear cells by vaginal fluid from women with a malignant adnexal mass. <b>2015</b> , 137, 2879-84	7
497	Mining the Human Proteome: Biomarker Discovery for Human Cancer and Metastases. <b>2015</b> , 21, 327-36	8
496	Postmenopausal Meigs' Syndrome in Elevated CA-125: A Case Report. <b>2015</b> , 21, 56-9	8
495	Serum fucosylated prostate-specific antigen (PSA) improves the differentiation of aggressive from non-aggressive prostate cancers. <b>2015</b> , 5, 267-76	53
494	Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study. <b>2015</b> , 10, e0121112	22
493	The O-Linked Glycome and Blood Group Antigens ABO on Mucin-Type Glycoproteins in Mucinous and Serous Epithelial Ovarian Tumors. <b>2015</b> , 10, e0130197	19
492	BAI1-Associated Protein 2-Like 1 (BAIAP2L1) Is a Potential Biomarker in Ovarian Cancer. <b>2015</b> , 10, e0133081	14
491	Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms: Clinical correlates. <b>2015</b> , 137, 430-5	24
490	Comparison of specific ovarian tumor markers by elecsys analyzer 2010. <b>2015</b> , 23, 86-9	5
489	Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array. <b>2015</b> , 21, 4960-9	44
488	Effectiveness of the risk of malignancy index and the risk of ovarian malignancy algorithm in a cohort of women with ovarian cancer: does histotype and stage matter?. <i>International Journal of Gynecological Cancer</i> , <b>2015</b> , 25, 809-14	3.5 13
487	Cellular leiomyoma with necrosis and mucinous degeneration presenting as pseudo-Meigs' syndrome with elevated CA125. <b>2015</b> , 33, 3033-7	10
486	Urinary microRNA-30a-5p is a potential biomarker for ovarian serous adenocarcinoma. <b>2015</b> , 33, 2915-23	113

485	Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women. <b>2015</b> , 36, 1045-53	30
484	Coexistence of benign struma ovarii, pseudo-Meigs' syndrome and elevated serum CA 125: Case report and review of the literature. <b>2015</b> , 9, 1739-1742	10
483	Costs, effectiveness, and workload impact of management strategies for women with an adnexal mass. <b>2015</b> , 107, 322	11
482	Ovarian cancer screening based on mixture change-point model. <b>2015</b> , 28, 471-488	1
481	Assessing the risk of ovarian malignancy algorithm for the conservative management of women with a pelvic mass. <b>2015</b> , 139, 248-52	9
480	Relative Quantification and Higher-Order Modeling of the Plasma Glycan Cancer Burden Ratio in Ovarian Cancer Case-Control Samples. <b>2015</b> , 14, 4394-401	17
479	ROMA, an algorithm for ovarian cancer. <b>2015</b> , 440, 143-51	40
478	Autoantibody signature for the serologic detection of ovarian cancer. <b>2015</b> , 14, 578-86	70
477	A case of ovarian fibroma masquerading as a uterine fibroid. <b>2016</b> , 4514-4518	1
476	The Establishment of an HE4-CLIA Method and the Combined Analysis of HE4 and CA125 in Ovarian Cancer. <b>2016</b> , 30, 709-18	7
475	Refining Ovarian Cancer Test accuracy Scores (ROCKETS): protocol for a prospective longitudinal test accuracy study to validate new risk scores in women with symptoms of suspected ovarian cancer. <b>2016</b> , 6, e010333	7
474	High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma. <b>2016</b> , 9, 41	22
473	Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers. <i>International Journal of Gynecological Cancer</i> , <b>2016</b> , 26, 43-51	3.5 143
472	The diagnosis and pathological value of combined detection of HE4 and CA125 for patients with ovarian cancer. <b>2016</b> , 11, 125-132	14
471	Protein Z: A putative novel biomarker for early detection of ovarian cancer. <b>2016</b> , 138, 2984-92	35
470	[Before surgery predictability of malignant ovarian tumors based on ADNEX model and its use in clinical practice]. <b>2016</b> , 44, 557-564	9
469	Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2016</b> , 25, 1333-40	4 31
468	The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer. <b>2016</b> , 5, 41-44	43

467	[Purple-bluish tongue is associated with platelet counts, and the recurrence of epithelial ovarian cancer]. <b>2016</b> , 36, 321-5	9
466	Evaluation and Management of Ultrasonographically Detected Ovarian Tumors in Asymptomatic Women. <b>2016</b> , 127, 848-858	23
465	Differences in the Molecular Species of CA125 Across the Phases of the Menstrual Cycle. <b>2016</b> , 18, 23-30	2
464	Metabolomics of biomarker discovery in ovarian cancer: a systematic review of the current literature. <b>2016</b> , 12, 1	42
463	Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer. <b>2016</b> , 293, 645-50	10
462	MAGE-A family serves as poor prognostic markers and potential therapeutic targets for epithelial ovarian cancer patients: a retrospective clinical study. <b>2017</b> , 33, 480-484	6
461	Ovarian Cancer Biomarkers in Circulation. <b>2017</b> , 371-398	
460	Minimally Invasive Adnexal Mass Extraction: Considerations and Techniques (With Videos). <b>2017</b> , 24, 182-188	2
459	Performance of ROMA based on Architect CA 125 II and HE4 values in Chinese women presenting with a pelvic mass: A multicenter prospective study. <b>2017</b> , 471, 119-125	9
458	Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center. <b>2017</b> , 22, 631-637	60
457	Frontiers in Ovarian Cancer Science. <b>2017</b> ,	1
456	Clinical performance of LOCI-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers. <b>2017</b> , 39, 1010428317730246	13
455	Committee Opinion No. 716: The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk. <b>2017</b> , 130, e146-e149	26
454	Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection. <b>2017</b> , 147, 465-480	40
453	A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours. <i>British Journal of Cancer</i> , <b>2017</b> , 117, 666-674	8.7 29
452	Early screening of ovarian cancer. <b>2017</b> , 33, 463-474	2
451	Glycans and glycoproteins as specific biomarkers for cancer. <b>2017</b> , 409, 395-410	205
450	Cancer Biomarkers in Body Fluids. <b>2017</b> ,	2

449	ACR Appropriateness Criteria Ovarian Cancer Screening. <b>2017</b> , 14, S490-S499	7
448	Preoperative measurement of serum C-reactive protein: is it useful in the differential diagnosis of adnexal masses?. <b>2017</b> , 32, e83-e89	4
447	Integrated multiomic predictors for ovarian cancer survival. <b>2018</b> , 39, 860-868	4
446	Fludeoxyglucose F 18 PET/CT Assessment of Ovarian Cancer. <b>2018</b> , 13, 179-202	4
445	Assessment of Circulating Tumor Cells as a Predictive Biomarker of Histology in Women With Suspected Ovarian Cancer. <b>2018</b> , 49, 134-139	16
444	Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment. <b>2018</b> , 18, 177-186	20
443	The prognostic value of perioperative, pre-systemic therapy CA125 levels in patients with high-grade serous ovarian cancer. <b>2018</b> , 140, 247-252	12
442	Rare Obstructive Müllerian Anomaly with Endometriosis and Elevated CA-125. <b>2018</b> , 25, 936-937	
441	Evaluation of Serum Nidogen-2 as a Screening and Diagnostic Tool for Ovarian Cancer. <b>2018</b> , 83, 461-465	3
440	Screening for Ovarian Cancer. <b>2018</b> ,	
439	Assessment of Diagnostic Values among CA-125, RMI, HE4, and ROMA for Cancer Prediction in Women with Nonfunctional Ovarian Cysts. <b>2018</b> , 2018, 7821574	2
438	Preoperative serum levels of cancer antigen 125 and carcinoembryonic antigen ratio can improve differentiation between mucinous ovarian carcinoma and other epithelial ovarian carcinomas. <b>2018</b> , 61, 344-351	9
437	Correlation of CA-125 with different stages of endometriosis. <b>2018</b> , 11, 41	
436	Activatable probes for diagnosing and positioning liver injury and metastatic tumors by multispectral optoacoustic tomography. <b>2018</b> , 9, 3983	95
435	Elevated CA 125 in a CASE of Leaking Endometrioma. <b>2018</b> , 2018, 2385048	3
434	Normalization of abnormal plasma amino acid profile-based indexes in patients with gynecological malignant tumors after curative treatment. <b>2018</b> , 18, 973	8
433	Mechanism for the Decision of Ovarian Surface Epithelial Stem Cells to Undergo Neo-Oogenesis or Ovarian Tumorigenesis. <b>2018</b> , 50, 214-232	18
432	A rare case of ovarian Lymphangioma associated with chylous ascites and raised CA-125.. <b>2018</b> , 24,	

- 431 Evaluation in the predictive value of serum human epididymal protein 4 (HE4), cancer antigen 125 (CA 125) and a combination of both in detecting ovarian malignancy. **2018**, 35, 1
- 430 Malignant peritoneal mesothelioma in a woman with bilateral ovarian serous borderline tumour: Potential interactions between the two diseases. **2018**, 24, 39-42 2
- 429 GDF15 predict platinum response during first-line chemotherapy and can act as a complementary diagnostic serum biomarker with CA125 in epithelial ovarian cancer. **2018**, 18, 328 15
- 428 Relationship Between Serum Tumor-related Markers and Dietary Intakes in Korean Healthy Adults. **2018**, 7, 161-169 2
- 427 Discriminative value of CA-125, HE4, Risk of Malignancy Index II (RMI-II) and Risk of Malignancy Algorithm (ROMA) in the differential diagnosis of pelvic masses: conclusions from a referral Centre in Portugal. **2018**, 38, 1140-1145 5
- 426 Cytoreductive Surgery and Intraperitoneal Chemotherapy for Advanced Epithelial Ovarian Cancer. **2018**, 221-252
- 425 Sertoli, Enrico (1841–1910)Leydig, Franz von (1821–1908). **2019**, 380-380
- 424 Brandt, Murray Lampel (b. 1892)Andrews, Charles James (1876–1950). **2019**, 56-56
- 423 Pawlik, Karl (1849–1914). **2019**, 314-314
- 422 Douglas, James (1675–1742). **2019**, 127-127
- 421 Döerlein, Albert Siegmund Gustav (1860–1941). **2019**, 121-121
- 420 Cloquet, Jules Germain (1790–1883). **2019**, 85-85
- 419 Kleihauer, Enno (1927–2017) Betke, Klaus Hermann (1914–2011). **2019**, 219-220
- 418 Novel Approaches to Ovarian Cancer Screening. **2019**, 21, 75 19
- 417 Barton, Lyman Guy (1866–1944). **2019**, 30-31
- 416 Robin, Pierre (1867–1950). **2019**, 348-348
- 415 Sharp, Jane (c. 1670). **2019**, 381-382
- 414 Piskač, Ludwig (1854–1932). **2019**, 327-327



413 Asherman, Joseph (1889-1968). **2019**, 10-10

412 Baird, Dugald (1900-1986). **2019**, 16-17

411 Bracht, Erich Franz (1882-1969). **2019**, 55-55

410 Campbell, Kate Isabel (1899-1986). **2019**, 69-69

409 Camper, Pieter (1722-1789). **2019**, 70-70

408 Cochrane, Archibald Leman (1909-1988). **2019**, 87-88

407 Gigli, Leonardo (1863-1908). **2019**, 153-153

406 Gilliam, David Tod (1844-1923). **2019**, 154-154

405 Hicks, John Braxton (1823-1897). **2019**, 179-180

404 Hoboken, Nicolaas (1632-1678). **2019**, 183-184

403 Klikovich, Stanislav Casimirovich (1853-1910). **2019**, 221-221

402 Levret, Andr   (1703 -1780). **2019**, 240-241

401 Madlener, Max (1868-1951). **2019**, 255-255

400 Malmstr  m, Tage (1911-1995). **2019**, 257-257

399 Marshall, Victor Fray (1913-2001) Marchetti, Andrew Anthony (1901-1970) Krantz, Kermit Edward (1923-2007). **2019**, 262-263

398 Moir, John Chassar (1900-1977). **2019**, 284-285

397 Porro, Edoardo (1842-1902). **2019**, 329-329

396 Rubin, Isidor Clinton (1883-1958). **2019**, 357-358

395 Scarpa, Antonio (1752–1832). **2019**, 370-370

394 Semmelweis, Ignac Philipp (1818–1865). **2019**, 377-379

393 Waldeyer, Heinrich Wilhelm Gottfried (1836–1921). **2019**, 440-440

392 White, Charles (1728–1813). **2019**, 446-446

391 White, Priscilla (1900–1989). **2019**, 448-449

390 Arias-Stella, Javier (b. 1924). **2019**, 7-7

389 Ballantyne, John William (1861–1923). **2019**, 20-20

388 Barcroft, Joseph (1872–1947). **2019**, 22-22

387 Bard, Samuel (1742–1821). **2019**, 23-23

386 Bartholin, Caspar (1655–1738). **2019**, 29-29

385 Baudelocque, Jean-Louis (1746–1810). **2019**, 34-34

384 Bennewitz, Heinrich Gottlieb (c.1824). **2019**, 36-37

383 Blair-Bell, William (1871–1936). **2019**, 42-43

382 Boivin, Marie Anne Victoire (1773–1841). **2019**, 46-46

381 Bowen, John Templeton (1857–1940). **2019**, 53-53

380 Braun, Carl Rudolph (1823–1891). **2019**, 57-57

379 Burnham, Walter (1808–1883). **2019**, 61-62

378 Cary, William Hollenback (b. 1883). **2019**, 72-72

377 Chamberlen, Peter (1601–1683). **2019**, 74-75

376 Champetier de Ribes, Camille Louis Antoine (1848–1935). **2019**, 76-76

375 Cherney, Leonid Sergius (1907–1963). **2019**, 81-81

374 Clay, Charles (1801–1893). **2019**, 84-84

373 Cooper, Astley Paston (1768–1841). **2019**, 93-93

372 Cotte, Gaston (1879–1951). **2019**, 96-96

371 Donald, Archibald (1860–1937). **2019**, 122-122

370 Down, John Langdon (1828–1896). **2019**, 128-128

369 Duchenne, Guillaume Benjamin Amand (1806–1875). **2019**, 130-130

368 Ferguson, John Creery (1802–1865). **2019**, 141-141

367 Foley, Frederick Eugene Basil (1891–1966). **2019**, 144-144

366 Fothergill, William Edward (1865–1926). **2019**, 145-145

365 Gaskin, Ina May (b. 1940). **2019**, 150-150

364 Giffard, William (d. 1731). **2019**, 151-152

363 Goodell, William (1829–1894). **2019**, 155-155

362 Graaf, Regnier de (1641–1673). **2019**, 157-158

361 Graves, TW (c.1870). **2019**, 160-160

360 Gregg, Norman McAlister (1892–1966). **2019**, 162-162

359 Hamlin, Reginald Henry James (1908–1993) Hamlin, Catherine (b. 1923). **2019**, 167-167

358 Hanks, Horace Tracy (1837–1900). **2019**, 168-168

357 Haultain, Francis William Nicol (1861–1921). **2019**, 174-174

356 Hillis, David Sweeney (1873–1942). **2019**, 181-181

355 Holmes, Oliver Wendell (1809–1894). **2019**, 187-188

354 Hon, Edward Harry Gee (1917–2006). **2019**, 190-190

353 Hopkins, Harold Horace (1918–1994). **2019**, 191-192

352 Houston, John (1802–1845). **2019**, 193-193

351 Hübner, Max (1873–1947). **2019**, 195-195

350 Jacquemin, Étienne Joseph (1796–1872). **2019**, 202-203

349 Kennedy, Evory (1806–1886). **2019**, 211-211

348 Kiwisch, Franz Ritter von Rotterau (1814–1852). **2019**, 218-218

347 Lazard, Edmond Meyer (1876–1969). **2019**, 231-232

346 Le Fort, Léon Clément (1829–1893). **2019**, 236-236

345 Lever, John Charles Weaver (1811–1859). **2019**, 239-239

344 Lippes, Jack (b. 1924). **2019**, 244-245

343 Logothetopoulos, Konstantinos (1878–1961). **2019**, 249-249

342 Løset, Jørgen (1896–1981). **2019**, 250-250

341 Mackenrodt, Alwin Karl (1859-1925). **2019**, 254-254

340 Marker, Russell Earl (1902-1995). **2019**, 260-261

339 Mauriceau, François (1637-1709). **2019**, 265-265

o

338 Mercier, Louis Auguste (1811-1882). **2019**, 279-279

337 Montgomery, William Fetherston (1797-1859). **2019**, 287-287

336 Moro, Ernst (1874-1951). **2019**, 289-289

335 Müller, Johannes Peter (1801-1858). **2019**, 291-291

334 Murray, Robert Milne (1855-1904). **2019**, 292-292

333 Ould, Fielding (1710-1789). **2019**, 302-304

332 Penrose, Charles Bingham (1862-1925). **2019**, 315-316

331 Pfannenstiel, Hermann Johann (1862-1909). **2019**, 318-318

330 Pincus, Gregory Goodwin (1903-1967) Rock, John Charles (1890-1984). **2019**, 323-325

329 Pratt, Edwin Hartley (1849-1930). **2019**, 334-334

328 Pugh, Benjamin (1715-1798). **2019**, 335-337

327 Rodeck, Charles Henry (b. 1944). **2019**, 351-351

326 Röslin, Eucharius (d. 1526). **2019**, 352-354

325 Santorini, Giovanni Domenico (1681-1737). **2019**, 367-367

324 Schauta, Friedrich (1849-1919). **2019**, 371-371

323 Simpson, James Young (1811–1870). **2019**, 387-388

322 Smellie, William (1697–1763). **2019**, 393-395

321 Smith, Albert Holmes (1835–1885). **2019**, 396-396

320 Smithells, Richard Worthington (1924–2002). **2019**, 397-397

319 Steinbüchel, Richard von (1865–1952). **2019**, 408-408

318 Stroganoff, Vasili Vasilievich (1857–1938). **2019**, 418-418

317 Thoms, Herbert (1885–1972). **2019**, 426-426

316 Torpin, Richard Ivan (1891–1976). **2019**, 427-427

315 Trendelenburg, Friedrich (1844–1924). **2019**, 428-428

314 Wigand, Justus Heinrich (1769–1817) Martin, August Eduard (1847–1934). **2019**, 450-450

313 Wrigley, Arthur Joseph (1902–1983). **2019**, 459-460

312 Aveling, James Hobson (1828–1892). **2019**, 11-11

311 Baillie, Matthew (1761–1823). **2019**, 15-15

310 Barnes, Robert (1817–1907) Neville, William Cox (1855–1904). **2019**, 26-27

309 Bishop, Edward Harry (1913–1995). **2019**, 41-41

308 Bonney, William Francis Victor (1872–1953). **2019**, 47-47

307 Call, Emma Louise (1847–1937) Exner, Siegmund (1846–1926). **2019**, 67-68

306 Chaussier, François (1746–1828). **2019**, 80-80

305 Cyprianus, Abraham (1655/1660–1718). **2019**, 109-111

304 Dawes, Geoffrey Sharman (1918–1996). **2019**, 113-113

303 Dickinson, Robert Latou (1861–1950). **2019**, 120-120

302 Donald, Ian (1910–1987). **2019**, 123-124

301 Estes, William Lawrence (1855–1940). **2019**, 135-135

300 Farre, Arthur (1811–1887). **2019**, 139-139

299 Ferguson, James Kenneth Wallace (1907–1999). **2019**, 140-140

298 Filshie, Gilbert Marcus (b. 1941). **2019**, 142-143

297 Gordon, Alexander (1752–1799). **2019**, 156-156

296 Grfenberg, Ernst (1881–1957). **2019**, 159-159

295 Guillemeau, Jacques (1550–1612). **2019**, 163-164

294 Hayward, George (1791–1863). **2019**, 175-175

293 Heaney, Noble Sproat (1880–1955). **2019**, 176-176

292 Holmes, Rudolph Wieser (1870–1953). **2019**, 189-189

291 Keyes, Edward Lawrence (1843–1925). **2019**, 215-215

290 Krukenberg, Freidrich Ernst (1871–1946). **2019**, 225-225

289 Langenbeck, Conrad Johann Martin (1776–1851). **2019**, 228-228

288 Maygrier, Jacques Pierre (1771–1835). **2019**, 266-266

287 McCall, Milton Lawrence (1911–1963). **2019**, 268-268

286 McDowell, Ephraim (1771–1830). **2019**, 272-273

285 Meigs, Joe Vincent (1892–1963). **2019**, 276-276

284 Meyer, Robert Otto (1864–1947). **2019**, 281-281

283 Minnitt, Robert James (1889–1974). **2019**, 283-283

282 Moschowitz, Alexis Victor (1865–1933). **2019**, 290-290

281 Novak, Emil (1884–1957). **2019**, 298-299

280 Pajot, Charles (1816–1896). **2019**, 306-306

279 Paré-Ambroise (1510–1590). **2019**, 312-313

278 Philpott, Robert Hugh (b. 1927). **2019**, 319-321

277 Pollitzer, Sigmund (1859–1937). **2019**, 327-328

276 Pomeroy, Ralph Hayward (1867–1925). **2019**, 329-329

275 Ritgen, Ferdinand August Maria Franz von (1787–1867). **2019**, 345-345

274 Rymsdyk, Jan van (c.1750). **2019**, 361-362

273 Smead, Louis (c.1940) Jones, Thomas (c.1940). **2019**, 393-393

272 Storer, Horatio Robinson (1830–1922). **2019**, 417-417

271 Te Linde, Richard Wesley (1894–1985). **2019**, 425-425

270 Willughby, Percivall (1596–1685). **2019**, 453-453



269 Word, Samuel Buford (1907–1971). **2019**, 456-457

268 Wright, Marmaduke Burr (1803–1879). **2019**, 458-458

267 Credé, Carl Siegmund Franz (1819–1892). **2019**, 102-102

266 Fracastoro, Girolamo (1478–1553). **2019**, 146-146

265 Pantaleoni, D Commander (c. 1869). **2019**, 310-310

264 Papanicolaou, George Nicholas (1883–1962). **2019**, 311-311

263 Rueff, Jacob (1500–1558). **2019**, 359-360

262 Saling, Erich (b. 1925). **2019**, 362-362

261 Schiller, Walter (1887–1960). **2019**, 372-372

260 Turner, Henry Hubert (1892–1970). **2019**, 432-432

259 Wertheim, Ernst (1864–1920). **2019**, 444-444

258 Wharton, Thomas (1614–1673). **2019**, 445-445

257 Williams, John Whitridge (1866–1931). **2019**, 452-452

256 Harvey, William (1578–1657). **2019**, 170-171

255 Kelly, Howard Atwood (1858–1943). **2019**, 208-208

254 Liley, Albert William (1929–1983). **2019**, 243-243

253 Noeggerath, Emil Oscar Jacob Bruno (1827–1895). **2019**, 297-297

252 Robert, Heinrich Ludwig Ferdinand (1814–1878). **2019**, 346-346

251 Veres, János (1903–1979). **2019**, 436-436

250 Wassermann, August Paul von (1866–1925). **2019**, 441-441

249 Carus, Carl Gustav (1789–1869). **2019**, 71-71

248 Corner, George Washington (1889–1981) Allen, Willard Myron (1904–1993). **2019**, 94-95

247 Denonvilliers, Charles Pierre (1808–1872). **2019**, 117-117

246 Kehrer, Ferdinand Adolf (1837–1914). **2019**, 207-207

245 Langhans, Theodor (1839–1915). **2019**, 229-229

244 Malthus, Thomas Robert (1766–1834). **2019**, 259-259

243 Palmer, Raoul (1905–1985). **2019**, 309-309

0

242 Sturmdorf, Arnold (1862–1934). **2019**, 419-420

241 Saxtorph, Matthias (1740–1800). **2019**, 368-368

240 Green-Armytage, Vivian Bartley (1882–1961). **2019**, 161-161

239 Migration dynamics of ovarian epithelial cells on micro-fabricated image-based models of normal and malignant stroma. **2019**, 100, 92-104

7

238 Biomarkers of Gynecological Cancers. **2019**, 133-150

237 Role of Tumor Markers. **2019**, 233-244

236 Biomarkers in Cancer Therapy. **2019**,

1

235 Evaluation of lysophosphatidic acid in vaginal fluid as a biomarker for ovarian cancer: A pilot study. **2019**, 2, 100012

3

234 Roberts, James Boyd (1907–1980). **2019**, 347-347

- 233 Setting clinical performance specifications to develop and evaluate biomarkers for clinical use. **2019**, 56, 527-535 12
- 232 Preface. **2019**, xix-xix
- 231 Aburel, Eugen Bogdan (1899-1975). **2019**, 1-1
- 230 Baer, Karl Ernst Ritter von (1792-1876). **2019**, 14-14
- 229 Caldeyro-Barcia, Roberto (1921-1996). **2019**, 65-65
- 228 Dale, Henry Hallett (1875-1968). **2019**, 112-112
- 227 Erb, Wilhelm Heinrich (1840-1921). **2019**, 134-134
- 226 Fallopius, Gabriel (1523-1562). **2019**, 137-138
- 225 Gardner, Herman L. (1912-1982). **2019**, 148-149
- 224 Halban, Josef (1870-1937). **2019**, 165-165
- 223 Irving, Frederick Carpenter (1883-1957). **2019**, 201-202
- 222 Joseph, Sister Mary (1856-1939). **2019**, 203-204
- 221 Kegel, Arnold Henry (1894-1972). **2019**, 205-206
- 220 Landsteiner, Karl (1868-1943). **2019**, 226-227
- 219 Macafee, Charles Horner Greer (1898-1978). **2019**, 252-253
- 218 Naboth, Martin (1675-1721). **2019**, 293-293 o
- 217 Nuck, Anton (1650-1692). **2019**, 299-300
- 216 Paget, James (1814-1899). **2019**, 304-305

215 Read, Grantly Dick (1890–1959). **2019**, 338-339

214 Stein, Irving Freiler (1887–1976) Leventhal, Michael Leo (1901–1971). **2019**, 407-407

213 Tait, Robert Lawson (1845–1899). **2019**, 420-421

212 Uchida, Hajime (1921–1996). **2019**, 433-434

211 Vacca, Aldo (1941–2014). **2019**, 434-435

210 Walcher, Gustav Adolf (1856–1935). **2019**, 439-439

209 Youssef, Abdel Fattah (1924–2001). **2019**, 460-461

208 Zavanelli, William Angelo (b. 1926). **2019**, 461-462

207 Bibliography. **2019**, 463-507

206 Index. **2019**, 508-522

205 Pancreaticobiliary metastasis presenting as primary mucinous ovarian neoplasm: A systematic literature review. **2019**, 28, 109-115

4

204 Gynecologic cancers and solid organ transplantation. **2019**, 19, 1266-1277

15

203 Bevis, Douglas Charles Aitchison (1918–1994). **2019**, 38-38

202 Burns, John William (1884–1950) Marshall, Charles McIntosh (1901–1954). **2019**, 63-64

201 Clarke, Cyril Astley (1907–2000). **2019**, 82-83

200 Colebrook, Leonard (1883–1967). **2019**, 89-90

199 Cullen, Thomas Stephen (1868–1953). **2019**, 103-104

198 Friedman, Emanuel A. (b. 1926). **2019**, 147-148

197 Hallopeau, François Henri (1842-1919). **2019**, 166-166

196 Rigby, Edward (1747-1821). **2019**, 342-344

195 Rubin, Alan (1923-2011). **2019**, 357-357

194 White, George Reves (1866-1926). **2019**, 447-447

193 Allen, Edgar (1892-1943) Doisy, Edward Adelbert (1893-1986). **2019**, 4-4

192 Aschheim, Selmar (1878-1965) Zondek, Bernhard (1891-1966). **2019**, 8-9

191 Bandl, Ludwig (1842-1892). **2019**, 21-21

190 Behr, Hulusi (1889-1948). **2019**, 35-35

189 Bird, Geoffrey Colin (1922-2001). **2019**, 39-40

188 Blundell, James (1790-1878). **2019**, 45-45

187 Bourgeois, Louyse (1563-1636). **2019**, 48-49

186 Bourne, Aleck William (1886-1974). **2019**, 50-50

185 Bozzini, Philipp (1773-1809). **2019**, 54-54

184 Breisky, August (1832-1889). **2019**, 58-58

183 Chadwick, James Read (1844-1905). **2019**, 73-73

182 Chapman, Edmund (c.1680-1756). **2019**, 78-79

181 Collip, James Bertram (1892-1965). **2019**, 91-91

180 Coudray, Angélique Marguerite Le Boursier du (1715-1794). **2019**, 97-99

179 Couvelaire, Alexandre (1873–1948). **2019**, 100-100

178 Curtis, Arthur Hale (1881–1955)Fitz-Hugh, Thomas (1894–1963). **2019**, 108-108

177 DeLee, Joseph Bolivar (1869–1942). **2019**, 114-115

176 Denman, Thomas (1733–1815). **2019**, 116-116

175 Duhrssen, Alfred (1862–1933). **2019**, 131-131

174 Duncan, James Matthews (1826–1890). **2019**, 132-132

173 Euler, Ulf Svante von (1905–1983)Bergström, Karl Sune Detlof (1916–2004). **2019**, 136-137

172 Ferguson, James Haig (1863–1934). **2019**, 139-139

171 Hart, Alfred Purvis (1888–1954). **2019**, 169-169

170 Hesselbach, Franz Kaspar (1759–1816). **2019**, 179-179

169 Hinselmann, Hans (1884–1959). **2019**, 182-182

168 Hodge, Hugh Lennox (1796–1873). **2019**, 185-185

167 Hofbauer, Isford Isfred (1878–1961). **2019**, 186-186

166 Hunner, Guy LeRoy (1868–1957). **2019**, 197-197

165 Hunter, William (1718–1783). **2019**, 198-199

164 Klumpke, Augusta (1859–1927). **2019**, 222-222

163 Kobelt, Georg Ludwig (1804–1857). **2019**, 223-223

162 Kristeller, Samuel (1820–1900). **2019**, 224-224

161 Latzko, Wilhelm (1863–1945). **2019**, 230-230

160 Leeuwenhoek, Antonj van (1632–1723). **2019**, 234-235

159 Little, William John (1810–1894). **2019**, 246-247

158 Litzmann, Carl Conrad Theodor (1815–1890). **2019**, 248-248

157 Mahfouz, Naguib (1882–1974). **2019**, 255-256

156 Malpighi, Marcello (1628–1694). **2019**, 258-258

155 Maylard, Alfred Ernest (1854–1947). **2019**, 267-267

154 McCormick, Katharine Dexter (1875–1967). **2019**, 269-270

153 McDonald, Ian Alexander (1922–1990). **2019**, 271-271

152 McRoberts, William Alexander (1914–2006). **2019**, 274-275

151 Monsel, Leon (1816–1878). **2019**, 286-286

150 Morgagni, Giovanni Battista (1682–1771). **2019**, 288-288

149 Naegele, Franz Carl (1778–1851). **2019**, 293-294

148 Nihell, Elizabeth (b. 1723). **2019**, 295-296

147 O'Driscoll, Kieran (1920–2007). **2019**, 299-300

146 Palfyn, Jan (1650–1730). **2019**, 307-308

145 Pearl, Raymond (1879–1940). **2019**, 314-314

144 Pereyra, Armand Joseph (1904–1988). **2019**, 317-317

143 Poupart, François (1661–1709). **2019**, 334-334

142 Ramsey, Elizabeth Maplesden (1906–1993). **2019**, 337-337

141 Reinke, Friedrich Berthold (1862–1919). **2019**, 341-341

140 Retzius, Anders Adolf (1796–1860). **2019**, 342-342

139 Röger, Max (1853–1903). **2019**, 366-366

138 Scanzoni, Friedrich Wilhelm (1821–1891). **2019**, 369-369

137 Schuchardt, Karl August (1856–1901). **2019**, 373-373

136 Schultze, Bernhard Sigmund (1827–1919). **2019**, 374-375

135 Semm, Kurt Karl Stephan (1927–2003). **2019**, 376-376

134 Sheehan, Harold Leeming (1900–1988). **2019**, 383-384

133 Sigault, Jean René (b. 1740). **2019**, 386-386

132 Sims, James Marion (1813–1883). **2019**, 389-391

131 Smythe, Henry James Drew (1891–1983). **2019**, 398-399

130 Soranus (c. 78–138). **2019**, 401-401

129 Spalding, Alfred Baker (1874–1942). **2019**, 402-402

128 Spinelli, Pier Giuseppe (1862–1929). **2019**, 404-404

127 Stoeckel, Walter (1871–1961). **2019**, 414-414

126 Stopes, Marie Carmichael (1880–1958). **2019**, 415-416



125 Tanner, James Mourilyan (1920–2010). **2019**, 422-423

124 Tarnier, Étienne Stéphane (1828–1897). **2019**, 424-424

123 Tucker, Ervin Alden (1862–1902)McLane, James Woods (1839–1912). **2019**, 429-430

122 Tuohy, Edward Boyce (1908–1959). **2019**, 431-431

121 Willett, John Abernethy (1872–1932). **2019**, 451-451

120 Alcock, Benjamin (b. 1801). **2019**, 2-2

119 Barker, David James Purslove (1938–2013). **2019**, 24-25

118 Gartner, Hermann Treschow (1785–1827). **2019**, 150-150

117 Liggins, Graham Collingwood (1926–2010). **2019**, 242-242

116 Rāmier, Joseph Claude Anthelme (1774–1852). **2019**, 340-340

115 Shirodkar, Vithal Nagesh (1899–1971). **2019**, 385-385

114 Barr, Murray Llewellyn (1908–1995). **2019**, 28-28

113 Battey, Robert (1825–1895). **2019**, 33-33

112 Brenner, Fritz (1877–1969). **2019**, 59-59

111 Browne, Thomas (1605–1682). **2019**, 59-59

110 Burch, John Christopher (1900–1977). **2019**, 60-60

109 Caldwell, William Edgar (1880–1943)Moloy, Howard Carman (1903–1953). **2019**, 66-66

108 Doyle, Joseph Bernard (1907–1992). **2019**, 129-129

107 Huntington, James Lincoln (1880–1968). **2019**, 200-201

106 Kelsey, Frances Oldham (1914–2015). **2019**, 209-210

105 Kimball, Gilman (1804–1892). **2019**, 217-217

104 Lember, Antoine (1802–1851). **2019**, 237-237

103 Martius, Heinrich (1885–1965). **2019**, 264-264

102 Michaelis, Gustav Adolf (1798–1848). **2019**, 282-282

101 Piper, Edmund Brown (1891–1935). **2019**, 326-326

100 Robson, Michael Stephen (b. 1957). **2019**, 349-350

99 Sampson, John Albertson (1873–1946). **2019**, 363-363

98 Stearns, John (1770–1848). **2019**, 405-406

97 Voorhees, James Ditmars (1869–1929). **2019**, 438-438

96 Keep, Nathan Cooley (1800–1875). **2019**, 204-204

95 Apgar, Virginia (1909–1974). **2019**, 5-6

2

94 Bovie, William T (1882–1958). **2019**, 51-52

93 Deventer, Hendrik van (1651–1724). **2019**, 118-119

92 Hulka, Jaroslav Fabian (1930–2014). **2019**, 196-196

91 Mendelson, Curtis Lester (1913–2002). **2019**, 277-277

90 Neisser, Albert Ludwig Siegmund (1855–1916). **2019**, 295-295

89 O'Sullivan, James Vincent (1899-1976). **2019**, 301-301

88 Portal, Paul (1630-1703). **2019**, 330-330

87 Potter, Edith Louise (1901-1993). **2019**, 331-331

86 Sanger, Margaret Louise (1879-1966). **2019**, 364-365

85 Snow, John (1813-1858). **2019**, 400-400

84 Steiner, Paul (1902-1978). **2019**, 409-409

83 Vigneaud, Vincent du (1901-1978). **2019**, 437-437

82 Walthard, Max (1867-1933). **2019**, 441-441

81 Watkins, Thomas James (1863-1925). **2019**, 442-442

80 Ayre, James Ernest (1910-1974). **2019**, 12-13

79 Baldy, John Montgomery (1860-1934) Webster, John Clarence (1863-1950). **2019**, 18-19

78 Craigin, Edwin Bradford (1859-1918). **2019**, 101-101

77 Culpeper, Nicholas (1616-1654). **2019**, 105-107

76 Doppler, Christian Andreas (1803-1853). **2019**, 126-126

75 Dusb (d. 1734). **2019**, 133-133

74 Harvie, John (c.1710-1770). **2019**, 172-173

73 Houstoun, Robert (1678-1734). **2019**, 194-194

72 Kerr, John Martin Munro (1868-1960). **2019**, 214-214

71 Kielland, Christian Casper Gabriel (1871–1941). **2019**, 216-216

70 Langer, Carl Ritter von Edenburg (1819–1887). **2019**, 229-229

69 Lee, Robert (1793–1877) Frankenhauser, Ferdinand (1832–1894). **2019**, 233-233

68 Lugol, Jean Guillaume Auguste (1788–1851). **2019**, 251-252

67 Menon, Krishna (1908–1988). **2019**, 278-278

66 Mettauert, John Peter (1787–1875). **2019**, 280-280

65 Rousset, François (c. 1530–1603). **2019**, 355-356

64 Spiegelberg, Otto von (1830–1881). **2019**, 403-403

63 Wells, Thomas Spencer (1818–1897). **2019**, 443-443

62 Wolff, Caspar Friedrich (1733–1794). **2019**, 454-454

61 Woods, Charles Edwin (1886–1946). **2019**, 455-455

60 Aldridge, Albert Herman (1893–1983). **2019**, 2-3

59 Basset, Antoine (1882–1951). **2019**, 32-32

58 Blond, Kasper (1889–1964) Heidler, Hans (1889–1955). **2019**, 44-44

57 Channing, Walter (1786–1876). **2019**, 77-77

56 Clover, Joseph Thomas (1825–1882). **2019**, 86-86

55 Coombs, Robert Royston Amos (1921–2006). **2019**, 92-92

54 Donn, Alfred François (1801–1878). **2019**, 125-125

53 Hegar, Alfred (1830–1914). **2019**, 177-178

52 Kergaradec, Jacques Alexandre Le Jumeau (1787–1877). **2019**, 212-213

51 K tner, Otto Ernst (1848–1931). **2019**, 225-226

50 Leopold, Christian Gerhard (1846–1912). **2019**, 238-238

49 Pinard, Adolphe (1844–1934). **2019**, 322-322

48 Potter, Irving White (1868–1956). **2019**, 332-333

47 Skene, Alexander Johnston Chalmers (1837–1900). **2019**, 392-392

46 Steptoe, Patrick Christopher (1913–1988) Edwards, Robert Geoffrey (1925–2013). **2019**, 410-413

45 Can Presurgical Ultrasound Predict Survival in Women With Ovarian Masses?. *Ultrasound Quarterly*, **2019**, 35, 39-44 1.4

44 Oral Cancer Detection. **2019**, 4

43 Salivary Biomarkers in Oral Cancer. **2019**, 265-295 4

42 Ultrasensitive bioassay of epitope of Mucin-16 protein (CA 125) in human plasma samples using a novel immunoassay based on silver conductive nano-ink: A new platform in early stage diagnosis of ovarian cancer and efficient management. *International Journal of Biological Macromolecules*, **2019**, 126, 1255–1265 7.9 29

41 High-throughput approaches for precision medicine in high-grade serous ovarian cancer. *Journal of Hematology and Oncology*, **2020**, 13, 134 22.4 12

40 Biomarkers and Strategies for Early Detection of Ovarian Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 2504-2512 4 22

39 Clinical usefulness of high levels of C-reactive protein for diagnosing epithelial ovarian cancer. *Scientific Reports*, **2020**, 10, 20056 4.9 2

38 Adnexal mass: diagnosis and management. *Revista Brasileira De Ginecologia E Obstetricia*, **2020**, 42, 438-443 1

37 Giant abdominal cyst in a young female patient: A case report. *International Journal of Surgery Case Reports*, **2020**, 72, 549-555 0.8 2

36 De novo prediction of cancer-associated T cell receptors for noninvasive cancer detection. *Science Translational Medicine*, **2020**, 12, 17.5 20

35	Grave Illness[] <i>Clinical Thyroidology</i> , <b>2020</b> , 32, 139-141	0.1	
34	Reducing Ovarian Cancer Mortality Through Early Detection: Approaches Using Circulating Biomarkers. <i>Cancer Prevention Research</i> , <b>2020</b> , 13, 241-252	3.2	21
33	Label-free electrochemical immunosensor for detection of oncomarker CA125 in serum. <i>Microchemical Journal</i> , <b>2020</b> , 155, 104746	4.8	24
32	Development of a near infrared protein nanoprobe targeting Thomsen-Friedenreich antigen for intraoperative detection of submillimeter nodules in an ovarian peritoneal carcinomatosis mouse model. <i>Biomaterials</i> , <b>2020</b> , 241, 119908	15.6	3
31	Pre-operative sera interleukin-6 in the diagnosis of high-grade serous ovarian cancer. <i>Scientific Reports</i> , <b>2020</b> , 10, 2213	4.9	17
30	Improved early detection of ovarian cancer using longitudinal multimarker models. <i>British Journal of Cancer</i> , <b>2020</b> , 122, 847-856	8.7	31
29	A novel electrochemical immunosensor for ultrasensitive detection of CA125 in ovarian cancer. <i>Biosensors and Bioelectronics</i> , <b>2020</b> , 153, 112029	11.8	45
28	Clinical significance of combining salivary mRNAs and carcinoembryonic antigen for ovarian cancer detection. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>2021</b> , 81, 39-45	2	3
27	Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. <i>Cancer</i> , <b>1995</b> , 76, 2092-2096	6.4	6
26	A History of Endoscopic Surgery. <b>1995</b> , 3-20		11
25	Prophylactic Surgery and Inherited Cancer Predisposition. <b>1999</b> , 103-133		1
24	Prognostic factors in ovarian cancer. <i>Cancer Treatment and Research</i> , <b>1998</b> , 95, 287-352	3.5	15
23	Diagnostic and therapeutic advances in gynecologic oncology: screening for gynecologic cancer. <i>Cancer Treatment and Research</i> , <b>1998</b> , 95, 253-76	3.5	8
22	Tumors of the Female Reproductive Organs. <b>1998</b> , 916-924		4
21	A comparison of color flow Doppler and serum CA 125 measurement in the preoperative evaluation of a complex pelvic mass. <i>International Journal of Gynecological Cancer</i> , <b>1998</b> , 8, 113-118	3.5	6
20	CA19-9 elevation in ovarian mature cystic teratoma: discrimination from ovarian cancer - CA19-9 level in teratoma. <i>Medical Science Monitor</i> , <b>2013</b> , 19, 230-5	3.2	22
19	Diagnostic value of human epididymis protein 4 compared with mesothelin for ovarian cancer: a systematic review and meta-analysis. <i>Asian Pacific Journal of Cancer Prevention</i> , <b>2012</b> , 13, 5427-32	1.7	21
18	Ovarian masses: is multi-detector computed tomography a reliable imaging modality?. <i>Asian Pacific Journal of Cancer Prevention</i> , <b>2013</b> , 14, 2627-30	1.7	6

17	Methylation status and immunohistochemistry of BRCA1 in epithelial ovarian cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , <b>2014</b> , 15, 9479-85	1.7	7
16	Impact of Preoperative Serum Levels of CA 125 on Epithelial Ovarian Cancer Survival. <i>Asian Pacific Journal of Cancer Prevention</i> , <b>2016</b> , 17, 1881-6	1.7	9
15	Ovaries and Fallopian Tubes. <i>Medical Radiology</i> , <b>2000</b> , 247-281	0.2	
14	Die Abklärung eines Adnexbefundes. <b>2002</b> , 74-90		
13	Tumors of the Female Reproductive Organs. <b>2003</b> , 887-894		
12	Postmenopausal Pelvis. <b>2008</b> , 1017-1035		
11	Culture systems for the human embryo. <b>2008</b> , 219-240		
10	Preoperative preparation and surgical instrumentation. <b>2010</b> , 24-36		
9	Clinical significance of preoperative serum CA-125 level in epithelial ovarian cancer. <i>Korean Journal of Obstetrics &amp; Gynecology</i> , <b>2012</b> , 55, 69		
8	Robert Edwards: The path to IVF*. <b>2012</b> , xxiii-xl		
7	Ovarian Cancer Screening and Early Detection in Low- and Middle-Income Countries. <b>2013</b> , 125-148		
6	Algo de historia del "Bebí Probeta". <i>Revista Colombiana De Obstetricia Y Ginecologia</i> , <b>1991</b> , 42, 158-162	0.1	
5	The management of ovarian cancer. <b>1997</b> , 85-89		
4	Testing for Breast Cancer Risk in the Ashkenazim. <b>1999</b> , 65-80		
3	Eponyms and Names in Obstetrics and Gynaecology. <b>2019</b> ,		0
2	Increased levels of serum CA-125 antigen in patients with non-Hodgkin's lymphoma. <b>2002</b> , 4, 459-460		
1	Complications of Oocyte Retrieval. <b>2022</b> , 287-298		0